---
title: "Biotech distress: going concern, bankruptcy and layoffs"
url: "https://aibio.space/distress/"
publisher: "aibio.space (Biotech Investor Relations News)"
summary: "285 stories, updated every morning. Going-concern warnings, bankruptcies, restructurings, staff cuts and sharp stock drops at public biotech companies…"
---

# Distress

Going-concern warnings, bankruptcies, restructurings, staff cuts and sharp stock drops at public biotech companies, newest first.

Distress · 2026-10-29

## [Mineralys takes ownership of lorundrostat patents but keeps Tanabe milestone debts](https://aibio.space/news/mineralys-takes-ownership-lorundrostat-patents-but-keeps-tanabe/)

A termination agreement ends the license and assigns the patents and know-how to Mineralys. Up to $255.0 million in commercial milestones still applies.

MLYS

A supreme court building with lit columns. CC0, via rawpixel

Distress

### [Bristol Myers Squibb drops Prothena's PRX019, ending up to $617.5 million in milestones](https://aibio.space/news/bristol-myers-squibb-drops-prothenas-prx019-ending-up-617-5-million/)

Bristol Myers Squibb will end its PRX019 license on January 28, 2027, dropping up to $617.5 million in milestones it could have owed. The 8-K cites an internal strategic review and gives no further reason.

PRTA

2026-10-29

Distress

### [LENZ Therapeutics reorganizes to cut 2027 operating expenses by more than 50%](https://aibio.space/news/lenz-therapeutics-reorganizes-cut-2027-operating-expenses-more-50/)

The VIZZ maker targets approximately $70 million to $75 million in 2027 operating expenses, and CEO Eef Schimmelpennink will step down December 1, 2026.

LENZ

2026-10-28

Distress

### [Artiva drops AlloNK, cuts about 94% of staff and weighs strategic alternatives](https://aibio.space/news/artiva-drops-allonk-cuts-about-94-percent-staff-weighs-strategic/)

The company ended AlloNK development after two patient deaths and durability data that did not meet its threshold. It reported about $319.1 million in cash, cash equivalents and investments at September 30, 2026, a preliminary figure.

ARTV

2026-10-27

Distress

### [Sangamo ends July in Chapter 11 with $16,906,955 in cash](https://aibio.space/news/sangamo-ends-july-chapter-11-16-906-955-cash/)

An amended monthly operating report for the period ended July 31, 2026 shows $16,906,955 in cash and a July loss of $11,165,298. It also lists an $18 million replacement debtor-in-possession loan.

SGMOQ

2026-10-27

## More distress news

1. Distress · 2026-10-26 [Supernus ends its UBS credit line ahead of the Indivior merger](https://aibio.space/news/supernus-ends-ubs-credit-line-ahead-indivior-merger/) Supernus ended its UBS credit line on October 20, 2026, with nothing drawn and no penalty. The filing says the combined company is to enter a new senior secured facility at closing, but it gives no closing date and no terms. [SUPN](https://aibio.space/companies/supernus-pharmaceuticals/)
2. Distress · 2026-10-22 [Fractyl cuts about 45% of staff and drops Rejuva gene therapy to fund Revita filing](https://aibio.space/news/fractyl-cuts-about-45-percent-staff-drops-rejuva-gene-therapy-fund/) The company expects quarterly cash burn to fall by about half, to roughly $8 million, and says its cash lasts into the second quarter of 2027. [GUTS](https://aibio.space/companies/fractyl-health/)
3. Distress · 2026-10-19 [EyePoint cuts about half its staff after second Duravyu wet AMD phase 3 miss](https://aibio.space/news/eyepoint-cuts-about-half-staff-after-second-duravyu-wet-amd-phase-3/) Lucia missed its non-inferiority goal against Eylea. EyePoint will end both wet AMD trials early and put its cash behind two diabetic macular edema studies due in late 2027. [EYPT](https://aibio.space/companies/eyepoint/)
4. Distress · 2026-10-19 [Collegium pays Grünenthal $17,000,000 to settle Nucynta suit and end license](https://aibio.space/news/collegium-pays-grunenthal-17-000-000-settle-nucynta-suit-end-license/) Collegium will pay Grünenthal $17,000,000 to end a February 2026 patent suit and a Nucynta license that carried royalties. The 8-K does not say what those royalties cost the company. [COLL](https://aibio.space/companies/collegium-pharmaceutical/)
5. Distress · 2026-10-16 [Fractyl shares fall 48% even as Revita meets six-month REMAIN-1 endpoint](https://aibio.space/news/fractyl-shares-fall-48-percent-even-revita-meets-six-month-remain-1/) Patients kept about 80% of their tirzepatide weight loss after one Revita procedure versus 67% after sham. Fractyl plans a De Novo filing in late fourth quarter 2026. [GUTS](https://aibio.space/companies/fractyl-health/)
6. Distress · 2026-10-14 [Liquidia to pay net $175 million in global settlement with United Therapeutics](https://aibio.space/news/liquidia-pay-net-175-million-global-settlement-united-therapeutics/) The deal ends six lawsuits. Liquidia also owes $145.4 million in two installments due in 2027 and $60.3 million to other parties this month. [LQDA](https://aibio.space/companies/liquidia/)[UTHR](https://aibio.space/companies/united-therapeutics/)
7. Distress · 2026-10-06 [Premier Air Charter says lessors terminated its CJ3 aircraft leases](https://aibio.space/news/premier-air-charter-says-lessors-terminated-cj3-aircraft-leases/) The company did not cure asserted defaults, returned two Citation CJ3 aircraft on October 1, 2026, and lessors claim approximately $514,557 under the leases. [PREM](https://aibio.space/companies/premier-air-charter/)
8. Distress · 2026-10-06 [Caribou explores strategic alternatives and ends its allogeneic CAR-T programs](https://aibio.space/news/caribou-explores-strategic-alternatives-ends-allogeneic-car-t-programs/) The Berkeley CRISPR company will discontinue vispa-cel and CB-011, cut staff and hire Wedbush. It had $113.8 million in cash on June 30 and expects $15 million to $19 million in restructuring costs. [CRBU](https://aibio.space/companies/caribou-biosciences/)
9. Distress · 2026-09-30 [Petros Pharmaceuticals assigns all assets to creditors and halts operations](https://aibio.space/news/petros-pharmaceuticals-assigns-all-assets-creditors-halts-operations/) Petros Pharmaceuticals assigned all of its assets to PT Liquidation, LLC for the benefit of creditors on September 30, 2026, and says it has ceased substantially all operations. The executive chairman and two directors resigned the same day, and the Series A preferred stock must be redeemed immediately. [PTPI](https://aibio.space/companies/petros-pharmaceuticals/)
10. Distress · 2026-09-29 [Lunai Bioworks delays annual report, expects net loss of about $3.2 million](https://aibio.space/news/lunai-bioworks-delays-annual-report-expects-net-loss-about-3-2-million/) The company, formerly Renovaro Inc., expects to file its Form 10-K for the year ended June 30, 2026 within the 15-day grace period. Its net loss for the prior year was about $178.0 million. [LNAI](https://aibio.space/companies/lunai-bioworks/)
11. Distress · 2026-09-28 [Advanced Biomed files late notice for annual report as audit is not complete](https://aibio.space/news/advanced-biomed-files-late-notice-annual-report-audit-not-complete/) Advanced Biomed told the SEC it could not file its annual report for the year ended June 30, 2026 on time because the audit was not finished. The notice does not name the auditor or explain the delay beyond that. [ADVB](https://aibio.space/companies/advanced-biomed/)
12. Distress · 2026-09-28 [Zeo ScientifiX says it cannot file its eight-month transition report on time](https://aibio.space/news/zeo-scientifix-says-cannot-file-eight-month-transition-report-time/) The Form 10-KT covers the eight months ended June 30, 2026. The company expects to file within the 15-day grace period. [ZEOX](https://aibio.space/companies/zeo-scientifix/)
13. Distress · 2026-09-25 [America Great Health says it cannot file its annual report by September 30, 2026](https://aibio.space/news/america-great-health-says-cannot-file-annual-report-september-30-2026/) The company filed a late-filing notice for the year ended June 30, 2026. It says it has not been able to compile the financial data for its Form 10-K. [AAGH](https://aibio.space/companies/america-great-health/)
14. Distress · 2026-09-23 [Adagio Medical starts strategic review and cuts workforce](https://aibio.space/news/adagio-medical-starts-strategic-review-cuts-workforce/) The board opened a formal process to explore alternatives that may include an acquisition, merger or other transaction, and the company has set no timetable. [ADGM](https://aibio.space/companies/adagio-medical/)
15. Distress · 2026-09-18 [Xenon pauses depression trial enrollment after psychosis reports, shares drop](https://aibio.space/news/xenon-pauses-depression-trial-enrollment-after-psychosis-reports/) The company stopped enrolling in its phase 3 MDD and bipolar studies of azetukalner. Fierce Biotech reported the shares fell 26% pre-market the next day. [XENE](https://aibio.space/companies/xenon-pharmaceuticals/)
16. Distress · 2026-09-14 [Sionna Therapeutics cuts about 46% of workforce, sees cash into second half of 2029](https://aibio.space/news/sionna-therapeutics-cuts-about-46-percent-workforce-sees-cash-second/) Sionna Therapeutics said it will cut about 46% of its workforce, expects about $6.4 million in restructuring charges, and expects its cash to last into the second half of 2029. The cuts follow a missed key endpoint for SION-719 in a Phase 2a trial. [SION](https://aibio.space/companies/sionna-therapeutics/)
17. Distress · 2026-09-08 [Evommune drops EVO756 in atopic dermatitis after phase 2b misses all endpoints](https://aibio.space/news/evommune-drops-evo756-atopic-dermatitis-after-phase-2b-misses-all/) The 121-patient trial failed at every dose. Evommune will keep testing EVO756 in migraine, move EVO301 forward and says cash lasts into 2029, a forecast that rests on revised plans. [EVMN](https://aibio.space/companies/evommune/)
18. Distress · 2026-09-02 [TScan cuts 75% of staff and pauses phase 3 trial for lack of capital](https://aibio.space/news/tscan-cuts-75-percent-staff-pauses-phase-3-trial-lack-capital/) TScan will cut about 75% of its workforce, stop enrolling its phase 3 ALLOHA-2 trial for lack of capital and focus on solid tumors. Amgen is also ending a Crohn's disease collaboration, and Nasdaq has warned that the stock failed the $1.00 minimum bid for 30 straight trading days. [TCRX](https://aibio.space/companies/tscan-therapeutics/)[AMGN](https://aibio.space/companies/amgen/)
19. Distress · 2026-08-28 [Teva bids $57.5 million upfront for BioXcel's agitation drug in bankruptcy sale](https://aibio.space/news/teva-bids-57-5-million-upfront-bioxcels-agitation-drug-bankruptcy-sale/) Teva is the stalking horse bidder for BioXcel's dexmedetomidine film, which faces an FDA decision on at-home use by Nov. 14. Other bidders can still top the offer. [TEVA](https://aibio.space/companies/teva-pharmaceutical-industries/)
20. Distress · 2026-08-27 [BioXcel files Chapter 11 with Teva as $57.5 million stalking horse bidder](https://aibio.space/news/bioxcel-files-chapter-11-teva-57-5-million-stalking-horse-bidder/) BioXcel filed Chapter 11 on Aug 27 with Teva's $57.5 million upfront bid as the floor for a court auction. That upfront sum is below the company's $107,152 thousand of total debt at June 30. [BTAI](https://aibio.space/companies/bioxcel-therapeutics-btai/)[TEVA](https://aibio.space/companies/teva-pharmaceutical-industries/)
21. Distress · 2026-08-25 [PTC agrees to buy Sangamo's Fabry gene therapy ST-920 in bankruptcy](https://aibio.space/news/ptc-agrees-buy-sangamos-fabry-gene-therapy-st-920-bankruptcy/) PTC Therapeutics will pay $111 million upfront and up to $100 million more in milestones for ST-920, subject to approval by the bankruptcy court. [PTCT](https://aibio.space/companies/ptc-therapeutics/)
22. Distress · 2026-08-25 [PDS Biotechnology to cut about 36% of workforce, removes Chief Operating Officer](https://aibio.space/news/pds-biotechnology-cut-about-36-percent-workforce-removes-chief/) PDS Biotechnology approved a reduction in force on August 6, 2026 and estimates a one-time charge of approximately $842,000. It also ended Stephan Toutain's role as Chief Operating Officer. [PDSB](https://aibio.space/companies/pds-biotechnology/)
23. Distress · 2026-08-17 [Outlook Therapeutics files NT 10-Q for June quarter, cites finance staff turnover](https://aibio.space/news/outlook-therapeutics-files-nt-10-q-june-quarter-cites-finance-staff/) Outlook says it cannot file its quarterly report on time because of its size, finance department turnover and work on a public offering that closed on August 14, 2026. It has a going concern warning in its last annual report. [OTLK](https://aibio.space/companies/outlook-therapeutics/)
24. Distress · 2026-08-14 [Curanex flags going-concern doubt with $2.94 million in cash at June 30](https://aibio.space/news/curanex-flags-going-concern-doubt-2-94-million-cash-june-30/) Curanex says its cash will not last twelve months, a reversal of the no-doubt finding in its first-quarter report. Prepaid research payments have so far held cash use well below its losses. [CURX](https://aibio.space/companies/curanex-pharmaceuticals/)
25. Distress · 2026-08-14 [Silexion had $2.2 million in cash at June 30 and flags going-concern doubt](https://aibio.space/news/silexion-had-2-2-million-cash-june-30-flags-going-concern-doubt/) Management said cash would last through the fourth quarter of 2026. The company has leaned on at-the-market sales and small offerings, and a Nasdaq delisting notice followed on August 18. [SLXN](https://aibio.space/companies/silexion-therapeutics/)
26. Distress · 2026-08-14 [Nutra Pharma files late-filing notice for its June 30, 2026 quarterly report](https://aibio.space/news/nutra-pharma-files-late-filing-notice-june-30-2026-quarterly-report/) Nutra Pharma filed a Form 12b-25 notice on August 14, 2026, saying its quarterly report for the period ended June 30, 2026 would be late. Its cash at December 31, 2025 was $12,181. [NPHC](https://aibio.space/companies/nutra-pharma/)
27. Distress · 2026-08-14 [ProtoKinetix files late-filing notice for its June 30, 2026 quarterly report](https://aibio.space/news/protokinetix-files-late-filing-notice-june-30-2026-quarterly-report/) The notice also says its 2025 Form 10-K and its March 31, 2026 Form 10-Q have not been filed. The company cites delays in finishing its financial statements and an auditor review. [PKTX](https://aibio.space/companies/protokinetix/)
28. Distress · 2026-08-13 [Sangamo bankruptcy auction brings in $163.55 million from PTC and Lilly](https://aibio.space/news/sangamo-bankruptcy-auction-brings-163-55-million-ptc-lilly/) Winning bids yield about $163.55 million in cash at closing and up to $100 million in milestones. Every sale still needs court approval, and the company is still selling other assets. [SGMOQ](https://aibio.space/companies/sangamo-therapeutics/)[LLY](https://aibio.space/companies/eli-lilly/)
29. Distress · 2026-08-13 [Polaryx reports $11.5 million cash, funding into early 2027 and going-concern doubt](https://aibio.space/news/polaryx-reports-11-5-million-cash-funding-early-2027-going-concern/) The company says its cash lasts through the first quarter of 2027 and it will need more capital after that. SOTERIA is due to start in the second half of 2026. [PLYX](https://aibio.space/companies/polaryx-therapeutics/)
30. Distress · 2026-08-13 [Pelthos Therapeutics says first-quarter 2026 financials can no longer be relied on, will restate](https://aibio.space/news/pelthos-therapeutics-says-first-quarter-2026-financials-can-no-longer/) Pelthos Therapeutics said on August 13, 2026 that its first-quarter 2026 financial statements can no longer be relied on. The restatement adds $14.8 million to the accumulated deficit, and the company reports a material weakness in its controls over convertible debt. [PTHS](https://aibio.space/companies/pelthos-therapeutics/)
31. Distress · 2026-08-13 [Regen Biopharma files late-filing notice for its June 30, 2026 quarterly report](https://aibio.space/news/regen-biopharma-files-late-filing-notice-june-30-2026-quarterly-report/) Regen Biopharma says a delay in its public accountant's review kept it from finishing the Form 10-Q for the period ended June 30, 2026. It says it will file within five calendar days of the due date. [RGBP](https://aibio.space/companies/regen-biopharma/)
32. Distress · 2026-08-12 [PTC named winning bidder for Sangamo's Fabry gene therapy ST-920](https://aibio.space/news/ptc-named-winning-bidder-sangamos-fabry-gene-therapy-st-920/) PTC says the ST-920 rolling BLA will be completed in the fourth quarter of 2026, with a potential commercial launch in 2027 if the acquisition closes. [PTCT](https://aibio.space/companies/ptc-therapeutics/)
33. Distress · 2026-08-12 [Turn Therapeutics ends June with $10.3 million and a going-concern warning](https://aibio.space/news/turn-therapeutics-ends-june-10-3-million-going-concern-warning/) Management says June 30 cash covers GX-03 work in atopic dermatitis into the third quarter of 2027, but the 10-Q also raises substantial doubt that Turn can continue as a going concern. [TTRX](https://aibio.space/companies/turn-therapeutics/)
34. Distress · 2026-08-11 [Aura Biosciences cuts about 20% of workforce, expects cash runway into 2029](https://aibio.space/news/aura-biosciences-cuts-about-20-percent-workforce-expects-cash-runway/) The company is refocusing on ocular oncology and minimizing resources for its bladder cancer program. Its Phase 3 CoMpass trial is fully enrolled with 108 patients. [AURA](https://aibio.space/companies/aura-biosciences/)
35. Distress · 2026-08-10 [Anavex Life Sciences files NT 10-Q, says June quarter report is late amid special committee review](https://aibio.space/news/anavex-life-sciences-files-nt-10-q-says-june-quarter-report-late-amid/) Anavex (Nasdaq: AVXL) cannot file its 10-Q for the quarter ended June 30, 2026 on time. The company also lists its 10-Q for the quarter ended March 31, 2026 as not yet filed. [AVXL](https://aibio.space/companies/anavex-life-sciences/)
36. Distress · 2026-08-10 [Anavex Life Sciences says it cannot file its June quarter report on time](https://aibio.space/news/anavex-life-sciences-says-cannot-file-june-quarter-report-time/) The company cites a special committee's review of matters tied to the April 30, 2026 termination of its chief executive. Its quarterly report for the period ended March 31, 2026 is also listed as not filed. [AVXL](https://aibio.space/companies/anavex-life-sciences/)
37. Distress · 2026-08-05 [Emergent BioSolutions posts $180.2 million Q2 loss, cuts about 90 roles](https://aibio.space/news/emergent-biosolutions-posts-180-2-million-q2-loss-cuts-about-90-roles/) A $191.3 million non-cash impairment charge drove the loss. The company expects annualized savings of approximately $40 million from the restructuring. [EBS](https://aibio.space/companies/emergent-biosolutions/)
38. Distress · 2026-08-04 [Bio-Rad starts restructuring plan with $80 to $90 million in pre-tax charges](https://aibio.space/news/bio-rad-starts-restructuring-plan-80-90-million-pre-tax-charges/) Bio-Rad Laboratories said on August 4, 2026 that the plan includes position eliminations and facility closures worldwide and is expected to be substantially completed by the end of fiscal year 2027. Second-quarter net sales were $651.0 million. [BIO](https://aibio.space/companies/nha-trang-vaccines-and-biological-products-jointstock/)
39. Distress · 2026-08-03 [Lisata cuts 72% of staff after failed Kuva buyout, then merges with Marea](https://aibio.space/news/lisata-cuts-72-percent-staff-after-failed-kuva-buyout-then-merges/) Kuva Labs could not raise the money to complete its $4.00 tender offer for Lisata. Lisata then cut about 72% of its staff, and on Sept 17 it bought Marea with a $225 million private placement that heavily dilutes existing holders. [LSTA](https://aibio.space/companies/lisata-therapeutics/)
40. Distress · 2026-07-23 [Summit files $380 million stock program as 10-Q flags going concern doubt](https://aibio.space/news/summit-files-380-million-stock-program-10-q-flags-going-concern-doubt/) Cash and short-term investments were $690.7 million at June 30. The company sold $230.8 million of stock in the second quarter through its ATM. [SMMT](https://aibio.space/companies/summit-therapeutics/)
41. Distress · 2026-07-22 [First Choice Healthcare amends deal for Florida pharmacy companies](https://aibio.space/news/first-choice-healthcare-amends-deal-florida-pharmacy-companies/) The amended agreement sets a maximum price of $21,306,000 for companies bought from seller Gary C. Bernard, M.D., and it depends on a related business combination that has not closed. [FCHS](https://aibio.space/companies/first-choice-healthcare-solutions/)
42. Distress · 2026-07-16 [Arbutus expects to return up to approximately $230M to shareholders](https://aibio.space/news/arbutus-expects-return-up-approximately-230m-shareholders/) Arbutus said it expects to begin returning up to about $230 million to shareholders in Q3 2026, but the form is not set, the board must approve it, and repurchases cannot start until a dividend from Genevant's parent arrives. The company received about $178 million from Moderna on July 8, 2026. [ABUS](https://aibio.space/companies/arbutus-biopharma/)[ROIV](https://aibio.space/companies/roivant-sciences/)
43. Distress · 2026-07-02 [Integrated BioPharma extends PNC revolving credit line to April 14, 2027](https://aibio.space/news/integrated-biopharma-extends-pnc-revolving-credit-line-april-14-2027/) The $4,000,000.00 PNC line now runs to April 14, 2027, and a new Convertible ELOC of up to $250,000.00 replaces a matured $500,000.00 equipment note. [INBP](https://aibio.space/companies/integrated-biopharma/)
44. Distress · 2026-06-23 [Boundless Bio signs merger agreement with Serapha Bio, cuts workforce by approximately 75%](https://aibio.space/news/boundless-bio-signs-merger-agreement-serapha-bio-cuts-workforce/) Boundless Bio agreed to an all-stock merger with privately held Serapha Bio and said it would cut about 75% of its workforce. After closing, Boundless holders would own about 3.69% of the combined company, and most of the early data behind the deal come from a trial in Shanghai. [BOLD](https://aibio.space/companies/boundless-bio/)
45. Distress · 2026-06-18 [SL Science closes Horizon Space Acquisition II deal, files shell company report](https://aibio.space/news/sl-science-closes-horizon-space-acquisition-ii-deal-files-shell/) SL Science Holding completed its merger with Horizon Space Acquisition II on June 12, 2026. Its shell company report says its three product candidates are still in preclinical testing, and that its financial statements carry a going-concern warning. [SLBT](https://aibio.space/companies/sl-science/)
46. Distress · 2026-06-15 [Polomar Health ends its Altanine merger and a patent license](https://aibio.space/news/polomar-health-ends-altanine-merger-patent-license/) Polomar and Altanine terminated their merger agreement as of June 12, 2026, and ended a related patent license. Polomar has until September 7, 2026, to sell remaining inventory under that license. [PMHS](https://aibio.space/companies/polomar-health-services/)
47. Distress · 2026-06-15 [Neumora to cut workforce about 35% and end navacaprant after Phase 3 studies miss endpoints](https://aibio.space/news/neumora-cut-workforce-about-35-percent-end-navacaprant-after-phase-3/) Neumora Therapeutics is ending development of navacaprant after its two Phase 3 KOASTAL trials in major depressive disorder missed statistical significance. It cut about 35% of its workforce and amended a loan with K2 HealthVentures, and it says its cash will last into the third quarter of 2027. [NMRA](https://aibio.space/companies/neumora-therapeutics/)
48. Distress · 2026-06-15 [enGene Therapeutics cuts workforce by about 50% in restructuring to preserve cash](https://aibio.space/news/engene-therapeutics-cuts-workforce-about-50-percent-restructuring/) enGene Therapeutics is cutting about 50% of its workforce and expects restructuring costs of $5.7 million to $6.4 million. It reported $285.2 million of cash at April 30, 2026, while its key trial data are interim and its FDA path depends on durability data not yet in hand. [ENGN](https://aibio.space/companies/engene-therapeutics/)
49. Distress · 2026-06-15 [enGene cuts about 50% of workforce, reports $285.2 million in cash](https://aibio.space/news/engene-cuts-about-50-percent-workforce-reports-285-2-million-cash/) The bladder cancer gene therapy developer stopped enrollment in three study cohorts to conserve cash. It plans to start its BLA filing in the second half of 2026. [ENGN](https://aibio.space/companies/engene-therapeutics/)
50. Distress · 2026-06-12 [Lipella's bankruptcy court approves sale of substantially all assets](https://aibio.space/news/lipellas-bankruptcy-court-approves-sale-substantially-all-assets/) A bankruptcy court approved the sale of substantially all of Lipella's assets to XRAIY LLC under an agreement dated May 14, 2026, in a chapter 11 case filed on March 30, 2026. [LIPO](https://aibio.space/companies/lipella-pharmaceuticals/)
51. Distress · 2026-06-04 [Fulcrum Therapeutics to cut workforce by approximately 85%, reviews strategic alternatives](https://aibio.space/news/fulcrum-therapeutics-cut-workforce-approximately-85-percent-reviews/) The restructuring follows the discontinuation of pociredir for sickle cell disease and carries expected charges of approximately $4.2 million. Leerink Partners LLC is advising the board. [FULC](https://aibio.space/companies/fulcrum-therapeutics/)
52. Distress · 2026-06-01 [Fulcrum Therapeutics drops pociredir and starts strategic review after FDA feedback](https://aibio.space/news/fulcrum-therapeutics-drops-pociredir-starts-strategic-review-after-fda/) Fulcrum ends pociredir, its lead sickle cell program, after FDA concerns about malignancy risk, and sets no timeline for its strategic review. It reported $333.3 million in cash, cash equivalents and marketable securities as of March 31, 2026. [FULC](https://aibio.space/companies/fulcrum-therapeutics/)
53. Distress · 2026-05-29 [American Shared Hospital Services discloses lender default notice](https://aibio.space/news/american-shared-hospital-services-discloses-lender-default-notice/) Fifth Third Bank's May 29, 2026 notice cites four specified events of default under the credit agreement and raises the interest rate to the default rate. [AMS](https://aibio.space/companies/american-shared-hospital-services/)
54. Distress · 2026-05-18 [Akari Therapeutics files NT 10-Q, cites public offering work and expected impairment](https://aibio.space/news/akari-therapeutics-files-nt-10-q-cites-public-offering-work-expected/) Akari Therapeutics says its quarterly report for the period ended March 31, 2026 will be late, partly because of work on an upcoming public offering. It also expects a material non-cash impairment charge, and its March 2026 annual report carried a going-concern paragraph. [AKTX](https://aibio.space/companies/akari-therapeutics/)
55. Distress · 2026-05-15 [Polomar Health waives Altanine merger conditions and amends CEO pact](https://aibio.space/news/polomar-health-waives-altanine-merger-conditions-amends-ceo-pact/) A May 11, 2026 consent and waiver letter sets aside several closing conditions and requires updated audited financial statements. A May 12 amendment cuts the chief executive's base salary to $19,000 a month. [PMHS](https://aibio.space/companies/polomar-health-services/)
56. Distress · 2026-05-15 [Apimeds Pharmaceuticals US files NT 10-Q, says quarterly report for March 31, 2026 will be late](https://aibio.space/news/apimeds-pharmaceuticals-us-files-nt-10-q-says-quarterly-report-march/) Apimeds (APUS) says it needs more time to finalize financial statements for the quarter ended March 31, 2026 and expects to file within a five-calendar-day extension. Its latest 10-K carries a going concern paragraph. [APUS](https://aibio.space/companies/apimeds-pharmaceuticals-us/)
57. Distress · 2026-05-15 [Exicure files NT 10-Q late filing notice, expects $1,827,911 first quarter net loss](https://aibio.space/news/exicure-files-nt-10-q-late-filing-notice-expects-1-827-911-first/) Exicure says it needs more time to finish its quarterly report and expects a net loss of approximately $1,827,911 for the quarter. Cash fell to about $2,504,054 by March 31, 2026, and its 10-K already carried a going-concern warning. [XCUR](https://aibio.space/companies/exicure/)
58. Distress · 2026-05-15 [Oramed Pharmaceuticals files NT 10-Q, says March 31, 2026 quarterly report will be late](https://aibio.space/news/oramed-pharmaceuticals-files-nt-10-q-says-march-31-2026-quarterly/) Oramed Pharmaceuticals says it needs more time to finish the financial statements for the quarter ended March 31, 2026, and expects to file within five calendar days of the due date. Its 2025 annual report showed a $7,675,000 Scilex note due March 31, 2026, and going-concern warnings at two companies it has invested in. [ORMP](https://aibio.space/companies/oramed-pharmaceuticals/)
59. Distress · 2026-05-15 [Scilex files NT 10-Q late filing notice, expects first quarter 10-Q by May 20, 2026](https://aibio.space/news/scilex-files-nt-10-q-late-filing-notice-expects-first-quarter-10-q-may/) Scilex Holding Company says it needs more time to finish its first-quarter 2026 financial statements, including the consolidation of Vivasor Holding Company, and expects to file by May 20, 2026. Its 2025 annual report carries a going-concern warning and an accumulated deficit of about $921.8 million. [SCLX](https://aibio.space/companies/scilex/)
60. Distress · 2026-05-15 [OS Therapies files NT 10-Q, says first-quarter report will be late after slower financial close](https://aibio.space/news/os-therapies-files-nt-10-q-says-first-quarter-report-will-late-after/) OS Therapies will miss the May 15, 2026 deadline for its first-quarter 10-Q and says it expects to file within the five-day extension. The filing comes from a company whose annual report, filed March 31, 2026, carries a going-concern warning and reports $269,830 of cash at year-end. [OSTX](https://aibio.space/companies/os-therapies/)
61. Distress · 2026-05-15 [ABVC BioPharma files NT 10-Q late-filing notice for quarter ended March 31, 2026](https://aibio.space/news/abvc-biopharma-files-nt-10-q-late-filing-notice-quarter-ended-march-31/) ABVC says it could not finalize its Form 10-Q and XBRL exhibit before the deadline without unreasonable effort or expense. Management believes it can file within the extension period. [ABVC](https://aibio.space/companies/abvc-biopharma/)
62. Distress · 2026-05-14 [Cell Source's delayed 10-Q shows $1,240 in cash and $11.1 million of past-due notes](https://aibio.space/news/cell-sources-delayed-10-q-shows-1-240-cash-11-1-million-past-due-notes/) Cell Source, an OTC Pink company, signed a 10-Q on May 14, 2026 for the quarter ended March 31, 2025. It reports $1,240 of cash, a going-concern warning, and notes past due, while it prepares a Nasdaq uplisting. [CLCS](https://aibio.space/companies/cell-source/)
63. Distress · 2026-05-11 [Anavex Life Sciences files late-filing notice for 10-Q after CEO termination](https://aibio.space/news/anavex-life-sciences-files-late-filing-notice-10-q-after-ceo/) Anavex Life Sciences told the SEC on May 11, 2026 that it cannot file its first-quarter 10-Q on time. The delay follows the April 30 termination of CEO Christopher Missling, and the company says the review of that termination may take longer than it expects. [AVXL](https://aibio.space/companies/anavex-life-sciences/)
64. Distress · 2026-05-07 [Arcturus Therapeutics reports $213.4 million in cash, sees runway past Q2 2028](https://aibio.space/news/arcturus-therapeutics-reports-213-4-million-cash-sees-runway-past-q2/) Operating expenses fell to $31.0 million from $46.2 million, but revenue fell by $27.3 million and the net loss was approximately $27.0 million. [ARCT](https://aibio.space/companies/arcturus-therapeutics/)
65. Distress · 2026-04-30 [Addex Therapeutics files late-filing notice for its 2025 annual report on Form 20-F](https://aibio.space/news/addex-therapeutics-files-late-filing-notice-2025-annual-report-form-20/) Addex Therapeutics filed a Form NT 20-F on April 30, 2026, saying it will miss the deadline for its 2025 annual report. It reported a 2025 net loss of CHF 6.7 million, against a 2024 profit of CHF 7.1 million that the company ties to a sale of part of its business. [ADXN](https://aibio.space/companies/addex-therapeutics/)
66. Distress · 2026-04-30 [Tiziana Life Sciences files late-filing notice for its 2025 annual report on Form 20-F](https://aibio.space/news/tiziana-life-sciences-files-late-filing-notice-2025-annual-report-form/) The company says compiling and reviewing the information has imposed time constraints. It undertakes to file no later than 15 days after the original due date. [TLSA](https://aibio.space/companies/tiziana-life-sciences/)
67. Distress · 2026-04-30 [XTL Biopharmaceuticals cannot file its 2025 Form 20-F, citing subsidiary liquidation](https://aibio.space/news/xtl-biopharmaceuticals-cannot-file-2025-form-20-f-citing-subsidiary/) The company says it lacks operational and financial data for its subsidiary The Social Proxy Ltd., which is in liquidation proceedings. [XTLB](https://aibio.space/companies/xtl-biopharmaceuticals/)
68. Distress · 2026-04-29 [Autolus Therapeutics to cut about 13% of workforce, expects about $8 million in charges](https://aibio.space/news/autolus-therapeutics-cut-about-13-percent-workforce-expects-about-8/) Autolus will cut about 13% of its workforce and expects about $8 million in severance and related charges, with savings of about $15 million a year from 2027. It reiterated 2026 AUCATZYL revenue guidance of $120 million to $135 million, while its 10-K reports a 2025 net loss of $287.5 million and cash used in operations of $283.6 million. [AUTL](https://aibio.space/companies/autolus-therapeutics/)
69. Distress · 2026-04-29 [Autolus Therapeutics cuts about 13% of staff, targets $15 million in annual savings](https://aibio.space/news/autolus-therapeutics-cuts-about-13-percent-staff-targets-15-million/) The company expects about $8 million in restructuring charges and continues to expect its cash to fund operations into the fourth quarter of 2027. [AUTL](https://aibio.space/companies/autolus-therapeutics/)
70. Distress · 2026-04-29 [Jyong Biotech files late-filing notice for its 2025 annual report on Form 20-F](https://aibio.space/news/jyong-biotech-files-late-filing-notice-2025-annual-report-form-20/) The company says it needs more time to finalize its audited financial statements and expects to file within 15 calendar days of the due date. [MENS](https://aibio.space/companies/jyong-biotech/)
71. Distress · 2026-04-21 [CASI Pharmaceuticals says 2025 Form 20-F is late, expects going-concern doubt](https://aibio.space/news/casi-pharmaceuticals-says-2025-form-20-f-late-expects-going-concern/) CASI Pharmaceuticals filed a Form NT 20-F on April 21, 2026, saying its annual report on Form 20-F for 2025 will be late because its U.S. GAAP financial statements are not yet available. It expects that report to say there remains substantial doubt about its ability to continue as a going concern. [CASIF](https://aibio.space/companies/casi-pharmaceuticals/)
72. Distress · 2026-04-21 [Lilly to end Rigel ocadusertib license effective June 15, 2026](https://aibio.space/news/lilly-end-rigel-ocadusertib-license-effective-june-15-2026/) Eli Lilly gave notice on April 16, 2026 that it is terminating its license for ocadusertib, a RIPK1 inhibitor, effective June 15, 2026. Rigel expects to regain full rights and does not expect future milestones or royalties under the agreement. [RIGL](https://aibio.space/companies/rigel-pharmaceuticals/)
73. Distress · 2026-04-20 [Semnur terminates two share purchase agreements tied to its 2025 merger](https://aibio.space/news/semnur-terminates-two-share-purchase-agreements-tied-2025-merger/) Semnur ended a private placement agreement with JW Capital Securities Limited and a share purchase agreement with Biconomy PTE. Ltd. Neither agreement had produced any issued shares. [SMNR](https://aibio.space/companies/semnur-pharmaceuticals/)
74. Distress · 2026-04-10 [Evofem amends Adjuvant convertible note terms and payment date](https://aibio.space/news/evofem-amends-adjuvant-convertible-note-terms-payment-date/) The Fourth Amendment, dated April 10, 2026, makes the notes payable in full at the earliest of three events. It bars prepayment for six months without Adjuvant's consent. [EVFM](https://aibio.space/companies/evofem-biosciences/)
75. Distress · 2026-04-01 [Quince Therapeutics (now IRulya Therapeutics) files NT 10-K after Phase 3 miss and staff cuts](https://aibio.space/news/quince-therapeutics-now-irulya-therapeutics-files-nt-10-k-after-phase/) The company says it needs more time to complete its 2025 annual report because of reduced headcount and negative Phase 3 results. It expects to file within the fifteen calendar day extension under Rule 12b-25. [IRLA](https://aibio.space/companies/irulya-therapeutics/)
76. Distress · 2026-04-01 [Scilex files NT 10-K, needs more time for financial statements including Vivasor consolidation](https://aibio.space/news/scilex-files-nt-10-k-needs-more-time-financial-statements-including/) Scilex Holding Company says it could not file its annual report by the March 31, 2026 due date and expects to file by April 15, 2026. It says it needs more time to finalize financial statements, including consolidating Vivasor Holding Company. [SCLX](https://aibio.space/companies/scilex/)
77. Distress · 2026-04-01 [China Pharma Holdings files NT 10-K for late annual report, estimates $3.19 million net loss](https://aibio.space/news/china-pharma-holdings-files-nt-10-k-late-annual-report-estimates-3-19/) China Pharma says it will file its 2025 annual report within fifteen calendar days after March 31, 2026. Its estimates show revenue of $4.1 million and a net loss of about $3.19 million, and its auditors have raised going-concern doubt before. [CPHI](https://aibio.space/companies/china-pharma/)
78. Distress · 2026-04-01 [TherapeuticsMD files late notice after printer error left out auditor report](https://aibio.space/news/therapeuticsmd-files-late-notice-after-printer-error-left-out-auditor/) TherapeuticsMD filed a Form 12b-25 notice on April 1, 2026 after a printer error left the predecessor auditor's report out of its 2025 annual report. The company reported a 2025 net loss of $569,000 and year-end cash of $7.5 million. [TXMD](https://aibio.space/companies/therapeuticsmd/)
79. Distress · 2026-03-31 [Greenwich LifeSciences, Inc. files NT 10-K, says annual report will be late](https://aibio.space/news/greenwich-lifesciences-inc-files-nt-10-k-says-annual-report-will-late/) Greenwich LifeSciences said on March 31, 2026 that its annual report for 2025 would be late. Its 2024 annual report already carried an auditor's going concern paragraph, with $4,091,990 in cash at year end against a $15,788,809 net loss. [GLSI](https://aibio.space/companies/greenwich-lifesciences/)
80. Distress · 2026-03-31 [GeoVax Labs files NT 10-K, says 2025 annual report will be late](https://aibio.space/news/geovax-labs-files-nt-10-k-says-2025-annual-report-will-late/) GeoVax missed the March 31, 2026 deadline for its 2025 annual report and expects to file within 15 days. It expects a 2025 net loss of about $21.5 million, and its 2024 annual report carried a going-concern warning from the auditors. [GOVX](https://aibio.space/companies/geovax-labs/)
81. Distress · 2026-03-31 [Traws Pharma files NT 10-K, cites financing efforts and going concern assessment](https://aibio.space/news/traws-pharma-files-nt-10-k-cites-financing-efforts-going-concern/) Traws Pharma filed a Form NT 10-K on March 31, 2026, saying it has not yet signed any financing and needs time to assess how a deal would affect its going-concern evaluation. The notice also gives unaudited 2025 net income of about $9.2 million, driven by a $26.7 million warrant accounting gain. [TRAW](https://aibio.space/companies/traws-pharma/)
82. Distress · 2026-03-31 [Sunshine Biopharma files NT 10-K, says annual report will be late](https://aibio.space/news/sunshine-biopharma-files-nt-10-k-says-annual-report-will-late/) Sunshine Biopharma filed a Form 12b-25 on March 31, 2026 for its 10-K for the year ended December 31, 2025. It cites time constraints and says it will file no later than fifteen days after the original due date. Its 2024 net loss was $5,134,116. [SBFM](https://aibio.space/companies/sunshine-biopharma/)
83. Distress · 2026-03-31 [TransCode Therapeutics files NT 10-K, says 2025 annual report will be late](https://aibio.space/news/transcode-therapeutics-files-nt-10-k-says-2025-annual-report-will-late/) TransCode blames the complexity of accounting for its October 2025 deal with DEFJ, LLC, including a roughly $25 million Series B preferred placement. It expects to file within the extension period. [RNAZ](https://aibio.space/companies/transcode-therapeutics/)
84. Distress · 2026-03-31 [Northwest Biotherapeutics says 10-K is late over Advent BioServices accounting](https://aibio.space/news/northwest-biotherapeutics-says-10-k-late-advent-bioservices-accounting/) The company cites issues tied to its Advent BioServices acquisition, including differences between UK GAAP and US GAAP. The notice gives no date for the annual report. [NWBO](https://aibio.space/companies/northwest-biotherapeutics/)
85. Distress · 2026-03-16 [Zevra agrees to sell SDX portfolio to Commave Therapeutics for $50 million](https://aibio.space/news/zevra-agrees-sell-sdx-portfolio-commave-therapeutics-50-million/) The deal settles a Delaware lawsuit. Zevra says it repaid its $63 million term loan in full before signing. [ZVRA](https://aibio.space/companies/zevra-therapeutics/)
86. Distress · 2026-03-09 [Genentech to end Xencor collaboration and license agreement September 4, 2026](https://aibio.space/news/genentech-end-xencor-collaboration-license-agreement-september-4-2026/) Genentech elected to terminate the agreement for convenience. Xencor says it expected the move. [XNCR](https://aibio.space/companies/xencor/)
87. Distress · 2026-03-06 [InMed Pharmaceuticals to wind down BayMedica, its only revenue-generating business](https://aibio.space/news/inmed-pharmaceuticals-wind-down-baymedica-only-revenue-generating/) InMed's board approved exiting BayMedica's sales on March 4, 2026. The company calls BayMedica its only revenue-generating business, expects about $550,000 in severance costs and about $120,000 in other spending, and its annual report already carries a going-concern warning. [INM](https://aibio.space/companies/inmed-pharmaceuticals/)
88. Distress · 2026-03-02 [GT Biopharma issues non-reliance notice, will restate June and September 2025 quarterly financials](https://aibio.space/news/gt-biopharma-issues-non-reliance-notice-will-restate-june-september/) On March 1, 2026 the audit committee concluded the quarterly reports contained an error: Greenshoe Rights from a May 2025 private placement required liability classification. GT Biopharma (Nasdaq: GTBP) will file Forms 10-Q/A. [GTBP](https://aibio.space/companies/gt-biopharma/)
89. Distress · 2026-03-02 [Acrivon ends Akoya companion diagnostic agreement and takes testing in-house](https://aibio.space/news/acrivon-ends-akoya-companion-diagnostic-agreement-takes-testing-house/) The February 25, 2026 termination involves no payments. Acrivon keeps full rights to its ACR-368 OncoSignature test. [ACRV](https://aibio.space/companies/acrivon-therapeutics/)
90. Distress · 2026-02-27 [XORTX auditor flags going-concern doubt in 2025 financials; cash was $864,514](https://aibio.space/news/xortx-auditor-flags-going-concern-doubt-2025-financials-cash-was-864/) The audit report says XORTX must finance its research or postpone it. The statements show an accumulated deficit of $23,824,557 at December 31, 2025. [XRTX](https://aibio.space/companies/xortx-therapeutics/)
91. Distress · 2026-02-26 [Viatris expects $700 million to $850 million in restructuring charges, plans up to 10% staff cut](https://aibio.space/news/viatris-expects-700-million-850-million-restructuring-charges-plans-up/) After an enterprise-wide strategic review, Viatris committed to restructuring that it expects to cut its global workforce by up to approximately 10%. It expects potential savings of between $600 million and $700 million. [VTRS](https://aibio.space/companies/viatris/)
92. Distress · 2026-02-23 [Galapagos (now Lakefront Biotherapeutics) lowers wind-down cost estimate, holds €3.0 billion](https://aibio.space/news/galapagos-now-lakefront-biotherapeutics-lowers-wind-down-cost-estimate/) The company lowered its expected cell therapy restructuring cash costs to €125 to €175 million. It expects to be a lean organization of about 35-40 employees by the end of 2026. [LKFT](https://aibio.space/companies/lakefront-biotherapeutics/)
93. Distress · 2026-02-13 [Werewolf Therapeutics cuts 64% of workforce; CFO and CMO resign](https://aibio.space/news/werewolf-therapeutics-cuts-64-percent-workforce-cfo-cmo-resign/) Werewolf expects a one-time charge of approximately $4.1 million in the first quarter of 2026. The filing also discloses the company's efforts to raise capital and a review of strategic partnerships for WTX-124 and WTX-330. [HOWL](https://aibio.space/companies/werewolf-therapeutics/)
94. Distress · 2026-02-04 [Maze Therapeutics signs Hercules loan of up to $200.0 million, draws $40.0 million](https://aibio.space/news/maze-therapeutics-signs-hercules-loan-up-200-0-million-draws-40-0/) The senior secured facility matures February 1, 2031. Maze ended its Banc of California loan agreement in connection with the deal. [MAZE](https://aibio.space/companies/maze-therapeutics/)
95. Distress · 2026-02-02 [UMeWorld (formerly UMeWorld Limited) says 10-Q is late after auditor resigned](https://aibio.space/news/umeworld-formerly-umeworld-limited-says-10-q-late-after-auditor/) UMeWorld filed a notice on February 2, 2026 that its quarterly report for the quarter ended December 31, 2025 will be late. Its auditor, J&S Associate PLT, resigned on December 31, 2025, and the company has not yet engaged a successor, so the review of its interim results has not started. [UMEW](https://aibio.space/companies/umeworld/)
96. Distress · 2026-01-30 [BGM Group files late notice for 20-F over XY Management acquisition accounting](https://aibio.space/news/bgm-group-files-late-notice-20-f-xy-management-acquisition-accounting/) BGM Group Ltd. says it cannot file its annual report on Form 20-F for the year ended September 30, 2025 on time. It is still finishing the consolidation and acquisition accounting for its purchase of YX Management Company Limited. [BGM](https://aibio.space/companies/bgm/)
97. Distress · 2025-12-16 [Geron begins restructuring, cutting about one-third of its roughly 260 employees](https://aibio.space/news/geron-begins-restructuring-cutting-about-one-third-roughly-260/) Geron Corporation estimates about $18 million in restructuring charges, mostly severance and benefits, and expects the workforce reduction to be substantially complete in the first quarter of 2026. [GERN](https://aibio.space/companies/geron/)
98. Distress · 2025-12-16 [Geron begins restructuring that cuts about one-third of its roughly 260 employees](https://aibio.space/news/geron-begins-restructuring-cuts-about-one-third-roughly-260-employees/) The company estimates about $18 million in restructuring charges, mostly severance and benefits, hitting results in the fourth quarter of 2025 and the first quarter of 2026. [GERN](https://aibio.space/companies/geron/)
99. Distress · 2025-12-15 [PharmaCyte Biotech files NT 10-Q for quarter ended October 31, 2025, citing need for more time](https://aibio.space/news/pharmacyte-biotech-files-nt-10-q-quarter-ended-october-31-2025-citing/) PharmaCyte Biotech will miss the December 15, 2025 deadline for its quarterly report and says it will file within five calendar days. The company's latest annual report says its licensed patents have expired and that the know-how for its core technology sits with a partner, while it has cut program spending during a board review. [PMCB](https://aibio.space/companies/pharmacyte-biotech/)
100. Distress · 2025-11-21 [Cullinan unit ends MIT license for CLN-617 after dropping the program](https://aibio.space/news/cullinan-unit-ends-mit-license-cln-617-after-dropping-program/) Cullinan Amber Corp. will return the licensed patent rights to MIT. The termination takes effect February 18, 2026. [CGEM](https://aibio.space/companies/cullinan-therapeutics/)
101. Distress · 2025-11-14 [Advanced Biomed files NT 10-Q, says review of September 30, 2025 quarter is not finished](https://aibio.space/news/advanced-biomed-files-nt-10-q-says-review-september-30-2025-quarter/) Advanced Biomed, which carried a going-concern warning and a Nasdaq bid price notice in its last annual report, says the review of its September 30, 2025 quarter is not finished. [ADVB](https://aibio.space/companies/advanced-biomed/)
102. Distress · 2025-11-14 [Q/C Technologies files NT 10-Q late-filing notice for its September 2025 quarterly report](https://aibio.space/news/q-c-technologies-files-nt-10-q-late-filing-notice-september-2025/) Q/C Technologies told the SEC on November 14, 2025 that it needs more time to finalize its quarterly report for the nine months ended September 30, 2025. The company filed its April 2025 annual report under the name TNF Pharmaceuticals, and that report carried a going-concern warning. [QCLS](https://aibio.space/companies/q-c-technologies/)
103. Distress · 2025-11-12 [Korro Bio cuts approximately 34% of workforce in restructuring, pauses Novo Nordisk deal](https://aibio.space/news/korro-bio-cuts-approximately-34-percent-workforce-restructuring-pauses/) Korro Bio cut about 34% of its workforce on November 12, 2025, paused its Novo Nordisk collaboration for 12 months, and said the moves extend its cash into the second half of 2027. Its chief medical officer also resigned, and its lead RNA editing candidate fell short of the protein levels the company had projected. [KRRO](https://aibio.space/companies/korro-bio/)
104. Distress · 2025-11-12 [Arcturus Therapeutics files NT 10-Q after technical error delays third-quarter report](https://aibio.space/news/arcturus-therapeutics-files-nt-10-q-after-technical-error-delays-third/) Arcturus blamed a technical transmission error for missing the deadline on its September 30, 2025 quarterly report. The notice gives no results, and the company's 2024 annual report shows cash use rising sharply. [ARCT](https://aibio.space/companies/arcturus-therapeutics/)
105. Distress · 2025-11-12 [Arcturus Therapeutics 10-Q gets November 12 filing date after transmission error](https://aibio.space/news/arcturus-therapeutics-10-q-gets-november-12-filing-date-after/) Arcturus says a technical transmission error caused it to miss the 5:30 PM Eastern deadline on November 10, 2025 for its quarterly report. Its commercial product is KOSTAIVE, a COVID-19 vaccine sold in Japan. [ARCT](https://aibio.space/companies/arcturus-therapeutics/)
106. Distress · 2025-11-12 [Korro Bio cuts about 34% of workforce, expects cash runway into second half of 2027](https://aibio.space/news/korro-bio-cuts-about-34-percent-workforce-expects-cash-runway-second/) The RNA editing company ended the third quarter of 2025 with $102.5 million in cash and securities. Its AATD drug candidate KRRO-110 did not reach projected protein levels. [KRRO](https://aibio.space/companies/korro-bio/)
107. Distress · 2025-11-03 [TScan Therapeutics cuts about 30% of workforce, 66 roles, to extend cash runway](https://aibio.space/news/tscan-therapeutics-cuts-about-30-percent-workforce-66-roles-extend/) TScan expects annual cost savings of $45.0 million in 2026 and 2027 and a one-time charge of up to approximately $2.3 million. It says its cash runway now extends into the second half of 2027. [TCRX](https://aibio.space/companies/tscan-therapeutics/)
108. Distress · 2025-11-03 [Gelteq files late notice for 20-F, says it needs more time on financials](https://aibio.space/news/gelteq-files-late-notice-20-f-says-needs-more-time-financials/) The company expects to file its annual report for the year ended June 30, 2025 within the fifteen-day grace period. [GELS](https://aibio.space/companies/gelteq/)
109. Distress · 2025-10-31 [Kazia Therapeutics says 20-F is late as audit procedures are not complete](https://aibio.space/news/kazia-therapeutics-says-20-f-late-audit-procedures-not-complete/) The company expects to file its annual report for the year ended June 30, 2025 no later than the fifteenth calendar day after the due date. [KZIA](https://aibio.space/companies/kazia-therapeutics/)
110. Distress · 2025-10-21 [Alector cuts workforce by about 49% after latozinemab Phase 3 trial misses endpoint](https://aibio.space/news/alector-cuts-workforce-about-49-percent-after-latozinemab-phase-3/) Alector expects $7.7 million in restructuring charges and reports a preliminary $291.1 million in cash and short-term investments at September 30, 2025. Its head of research and development is resigning. [ALEC](https://aibio.space/companies/alector/)
111. Distress · 2025-10-02 [Bolt Biotherapeutics cuts workforce by about 50% and extends cash runway into 2027](https://aibio.space/news/bolt-biotherapeutics-cuts-workforce-about-50-percent-extends-cash/) Bolt will cut about 20 employees, roughly 50% of its workforce, with pre-tax charges of $1.5 million to $2.0 million. The company says the cut extends its cash runway into 2027. Initial BDC-4182 clinical data, now expected in the third quarter of 2026, will come later after a protocol change. [BOLT](https://aibio.space/companies/bolt-biotherapeutics/)
112. Distress · 2025-10-02 [Theriva Biologics cuts 32% of workforce, expects cash runway into second quarter of 2026](https://aibio.space/news/theriva-biologics-cuts-32-percent-workforce-expects-cash-runway-second/) Theriva says cutting about seven employees, or 32% of its global workforce, and other cost cuts extend its cash runway into the second quarter of 2026. Its 2024 annual report carried a going-concern warning, and the company reported $11.6 million of cash and equivalents at December 31, 2024. [TOVX](https://aibio.space/companies/theriva-biologics/)
113. Distress · 2025-10-01 [KALA BIO receives Oxford Finance default notice, lender declares $29.1 million loan due](https://aibio.space/news/kala-bio-receives-oxford-finance-default-notice-lender-declares-29-1/) Oxford Finance says an event of default under a Material Adverse Change clause is continuing and has accelerated all obligations under the 2021 loan agreement. The notice says interest began accruing at the Default Rate, and that $29.1 million is now payable. [KALA](https://aibio.space/companies/kala-bio/)
114. Distress · 2025-09-29 [KALA BIO to cut 51% of workforce, ends KPI-012 after Phase 2b trial misses endpoint](https://aibio.space/news/kala-bio-cut-51-percent-workforce-ends-kpi-012-after-phase-2b-trial/) KALA BIO will stop developing KPI-012 and its stem cell secretome platform, cut approximately 19 employees and talk with its secured lender while it explores strategic options. [KALA](https://aibio.space/companies/kala-bio/)
115. Distress · 2025-09-29 [Sutro Biopharma plans to cut workforce by about one-third, expects cash runway into mid-2027](https://aibio.space/news/sutro-biopharma-plans-cut-workforce-about-one-third-expects-cash/) Sutro Biopharma (Nasdaq: STRO) plans a workforce reduction of approximately one-third to focus on three preclinical ADC programs. It estimates $4.1 million to $4.3 million in costs. [STRO](https://aibio.space/companies/sutro-biopharma/)
116. Distress · 2025-09-17 [Arvinas to cut about 15% of staff, seek vepdegestrant partner; approves $100 million buyback](https://aibio.space/news/arvinas-cut-about-15-percent-staff-seek-vepdegestrant-partner-approves/) Arvinas said on September 17, 2025 that it will cut its workforce by a further 15%, mainly in vepdegestrant commercialization roles, and that it will seek a third party to take over the drug with Pfizer. The same day its board authorized a buyback of up to $100 million, and the filing does not give the cash balance on which that depends. [ARVN](https://aibio.space/companies/arvinas/)
117. Distress · 2025-09-17 [X4 Pharmaceuticals cuts workforce by 50% in restructuring as four senior executives depart](https://aibio.space/news/x4-pharmaceuticals-cuts-workforce-50-percent-restructuring-four-senior/) X4 is cutting about 50% of its workforce for annualized savings of about $13 million, with cash charges of about $3.3 million, after three executives were terminated and its chief medical officer resigned. Its 2024 annual report carried a going-concern warning tied to a loan covenant with Hercules. [XFOR](https://aibio.space/companies/x4-pharmaceuticals/)
118. Distress · 2025-09-17 [Arvinas cuts about 15% of staff, authorizes $100 million buyback](https://aibio.space/news/arvinas-cuts-about-15-percent-staff-authorizes-100-million-buyback/) The company and Pfizer have agreed to out-license vepdegestrant commercialization rights and have begun looking for a partner. Arvinas expects about $4.5 million in workforce costs. [ARVN](https://aibio.space/companies/arvinas/)
119. Distress · 2025-09-12 [Benitec Biopharma says two quarterly financial reports should not be relied on, plans restatement](https://aibio.space/news/benitec-biopharma-says-two-quarterly-financial-reports-should-not/) Benitec's Audit Committee found share-based compensation expense was understated in the quarters ended December 31, 2024 and March 31, 2025. The company expects to file its 2025 annual report on time. [BNTC](https://aibio.space/companies/benitec-biopharma/)
120. Distress · 2025-09-08 [Abivax expects cash into Q4 2027 after $747.5 million gross offering](https://aibio.space/news/abivax-expects-cash-q4-2027-after-747-5-million-gross-offering/) Abivax reported a first-half net loss of EUR 100.8 million and negative shareholders' equity of EUR 48.3 million at June 30, 2025, before a July US offering and several note conversions. The company now says its cash lasts into the fourth quarter of 2027. [ABVX](https://aibio.space/companies/abivax/)
121. Distress · 2025-09-04 [AC Immune to cut about 30% of workforce, sees CHF 127.1 million lasting to Q3 2027](https://aibio.space/news/ac-immune-cut-about-30-percent-workforce-sees-chf-127-1-million/) The company is focusing on its late-stage active immunotherapy programs and two small molecule programs. It says near-term clinical milestones are unchanged. [ACIU](https://aibio.space/companies/ac-immune/)
122. Distress · 2025-08-26 [Indivior PLC (now Indivior Pharmaceuticals, Inc.) expects $39 to $50 million restructuring charges](https://aibio.space/news/indivior-plc-now-indivior-pharmaceuticals-inc-expects-39-50-million/) Indivior says its Action Agenda initiative brings headcount reductions and real estate consolidations. It expects $27 million to $35 million of the charges to be cash and is exploring strategic alternatives for OPVEE and its non-U.S. business. [INDV](https://aibio.space/companies/indivior-pharmaceuticals/)
123. Distress · 2025-08-19 [Evogene cuts 30% of workforce, reports $11.7 million cash and $18.71 million ICL sale](https://aibio.space/news/evogene-cuts-30-percent-workforce-reports-11-7-million-cash-18-71/) Evogene is cutting 30% of its workforce and says an $18.71 million asset sale and a $4.4 million share program give it an 18-month runway. The $11.7 million cash figure leaves out the sale proceeds, and the company's equity attributable to shareholders is negative. [EVGN](https://aibio.space/companies/evogene/)
124. Distress · 2025-08-15 [Cingulate files NT 10-Q, citing management changes, for quarter ended June 30, 2025](https://aibio.space/news/cingulate-files-nt-10-q-citing-management-changes-quarter-ended-june/) The company says it needs more time to review its financial statements after recent changes in management. It expects to file its Form 10-Q within the five calendar day period under Rule 12b-25. [CING](https://aibio.space/companies/cingulate/)
125. Distress · 2025-08-15 [OS Therapies files NT 10-Q late filing notice for second quarter, cites financial close delays](https://aibio.space/news/os-therapies-files-nt-10-q-late-filing-notice-second-quarter-cites/) OS Therapies could not file its quarterly report for the period ended June 30, 2025 by its August 14, 2025 due date. Its last annual report carried an auditor's going concern warning and showed $5,533,527 of cash at the end of 2024. [OSTX](https://aibio.space/companies/os-therapies/)
126. Distress · 2025-08-15 [Agentix Corp. says its June quarter report will be late](https://aibio.space/news/agentix-corp-says-june-quarter-report-will-late/) Agentix has no meaningful revenue, and its lead drug candidate has animal efficacy data only in its annual report. It says it cannot finish its quarterly report on time and expects to file by August 19, 2025. [AGTX](https://aibio.space/companies/agentix/)
127. Distress · 2025-08-15 [CERo Therapeutics delays Q2 report, estimates $18.5 million quarterly net loss](https://aibio.space/news/cero-therapeutics-delays-q2-report-estimates-18-5-million-quarterly/) The company needs more time to value marketable securities it received as part payment for Series D Preferred Stock. It estimates an $18.5 million net loss for the quarter and a $33.4 million loss attributable to common shareholders. [CERO](https://aibio.space/companies/cero-therapeutics/)
128. Distress · 2025-08-15 [Cingulate delays quarterly report after management changes](https://aibio.space/news/cingulate-delays-quarterly-report-after-management-changes/) Cingulate filed a late-filing notice for its report on the quarter ended June 30, 2025. It expects to file within the five-day extension period. [CING](https://aibio.space/companies/cingulate/)
129. Distress · 2025-08-15 [Cosmos Health files late notice for its June 30, 2025 quarterly report](https://aibio.space/news/cosmos-health-files-late-notice-june-30-2025-quarterly-report/) Cosmos Health said it could not finish its June 30, 2025 Form 10-Q on time, blaming delays in obtaining and compiling information, including its XBRL filing. It does not expect a significant change in results from a year earlier. [COSM](https://aibio.space/companies/cosmos-health/)
130. Distress · 2025-08-15 [HCW Biologics delays quarterly report for period ended June 30, 2025](https://aibio.space/news/hcw-biologics-delays-quarterly-report-period-ended-june-30-2025/) HCW Biologics says it needs more time to finish its June quarter 10-Q and expects to file within the five-day grace period. The notice gives no revenue, loss or cash figures. [HCWB](https://aibio.space/companies/hcw-biologics/)
131. Distress · 2025-08-15 [Liminatus Pharma files late notice for quarterly report for June 30, 2025](https://aibio.space/news/liminatus-pharma-files-late-notice-quarterly-report-june-30-2025/) The company said its financial statements could not be completed in time for review and signatures. It checked the box saying it will file within the grace period. [LIMN](https://aibio.space/companies/liminatus-pharma/)
132. Distress · 2025-08-15 [OS Therapies delays quarterly report for period ended June 30, 2025](https://aibio.space/news/os-therapies-delays-quarterly-report-period-ended-june-30-2025/) OS Therapies says it needs more time to finish its financial statement close for the quarter ended June 30, 2025, and expects to file within the five-day extension. [OSTX](https://aibio.space/companies/os-therapies/)
133. Distress · 2025-08-15 [Sigyn Therapeutics delays quarterly report for period ended June 30, 2025](https://aibio.space/news/sigyn-therapeutics-delays-quarterly-report-period-ended-june-30-2025/) Sigyn Therapeutics filed a Form 12b-25 notice on August 15, 2025 saying it cannot file its quarterly report for the period ended June 30, 2025 on time. It promises to file no later than five days after the original due date. [SIGY](https://aibio.space/companies/sigyn-therapeutics/)
134. Distress · 2025-08-14 [CDT Equity, formerly Conduit Pharmaceuticals, says Q1 2025 financials should not be relied on](https://aibio.space/news/cdt-equity-formerly-conduit-pharmaceuticals-says-q1-2025-financials/) The company says $0.4 million of milestone payments to Sarborg Limited were booked as research and development expense but should have been an acquired diagnostic asset. It plans to amend its first-quarter Form 10-Q. [CDT](https://aibio.space/companies/cdt-equity/)
135. Distress · 2025-08-14 [Allarity Therapeutics files NT 10-Q, says June 30, 2025 quarterly report will be late](https://aibio.space/news/allarity-therapeutics-files-nt-10-q-says-june-30-2025-quarterly-report/) Allarity says its auditors have not finished reviewing the quarter. It expects to file within five calendar days of the due date and does not anticipate a significant change in results from a year earlier. [ALLR](https://aibio.space/companies/allarity-therapeutics/)
136. Distress · 2025-08-14 [NRx Pharmaceuticals files NT 10-Q, says second-quarter Form 10-Q will be late](https://aibio.space/news/nrx-pharmaceuticals-files-nt-10-q-says-second-quarter-form-10-q-will/) NRx Pharmaceuticals (Nasdaq: NRXP) told the SEC it needs more time to compile information for its June 30, 2025 quarterly report. It expects to file within five calendar days of the due date. [NRXP](https://aibio.space/companies/nrx-pharmaceuticals/)
137. Distress · 2025-08-14 [Allarity Therapeutics delays quarterly report while auditors finish review](https://aibio.space/news/allarity-therapeutics-delays-quarterly-report-while-auditors-finish/) The company filed a late-filing notice on August 14, 2025 for its report on the quarter ended June 30, 2025. It expects to file within the extension period, but its auditors had not finished their review. [ALLR](https://aibio.space/companies/allarity-therapeutics/)
138. Distress · 2025-08-14 [Apimeds Pharmaceuticals delays quarterly report for period ended June 30, 2025](https://aibio.space/news/apimeds-pharmaceuticals-delays-quarterly-report-period-ended-june-30/) Apimeds says it cannot file its quarterly report for the period ended June 30, 2025 on time and expects to file within the five-day extension. Its lead drug, Apitox, rests on a prior Phase III trial that the company's own filing describes in conflicting terms. [APUS](https://aibio.space/companies/apimeds-pharmaceuticals-us/)
139. Distress · 2025-08-14 [Eloxx Pharmaceuticals lacks funds for auditor review, expects $0.6 million cash](https://aibio.space/news/eloxx-pharmaceuticals-lacks-funds-auditor-review-expects-0-6-million/) The company also has not filed its annual reports for 2023 and 2024. It expects to disclose substantial doubt about its ability to continue as a going concern. [ELOX](https://aibio.space/companies/eloxx-pharmaceuticals/)
140. Distress · 2025-08-14 [Goldenwell Biotech files late notice for June quarter report](https://aibio.space/news/goldenwell-biotech-files-late-notice-june-quarter-report/) Goldenwell said it could not compile its financial information in time and expects to file by August 19, 2025. Its notice also says an annual report has not been filed, and its latest filed balance sheet is small. [GWLL](https://aibio.space/companies/goldenwell-biotech/)
141. Distress · 2025-08-14 [Jupiter Neurosciences delays quarterly report for period ended June 30, 2025](https://aibio.space/news/jupiter-neurosciences-delays-quarterly-report-period-ended-june-30/) Jupiter said it needs more time to complete the presentation and review of its financial statements. It expects to file within five calendar days of the deadline and says it anticipates no significant change in results. [JUNS](https://aibio.space/companies/jupiter-neurosciences/)
142. Distress · 2025-08-14 [NRx Pharmaceuticals files late notice for quarterly report for June 30, 2025](https://aibio.space/news/nrx-pharmaceuticals-files-late-notice-quarterly-report-june-30-2025/) NRx told the SEC it will miss the regular deadline for its June quarter report and needs more time to compile information. It expects to file within the form's five-day grace period, and the notice gives no figures. [NRXP](https://aibio.space/companies/nrx-pharmaceuticals/)
143. Distress · 2025-08-14 [NeOnc Technologies delays quarterly report to finish review of stock unit charges](https://aibio.space/news/neonc-technologies-delays-quarterly-report-finish-review-stock-unit/) NeOnc needs more time to review non-cash expense charges tied to previously granted restricted stock units. It expects to file within five days. [NTHI](https://aibio.space/companies/neonc-technologies/)
144. Distress · 2025-08-14 [Ocean Biomedical delays quarterly report for period ended June 30, 2025](https://aibio.space/news/ocean-biomedical-delays-quarterly-report-period-ended-june-30-2025/) The company said it is working with its auditor to finish the review of its Form 10-Q. It expects to file within 5 calendar days of the due date. [OCEA](https://aibio.space/companies/ocean-biomediacal/)
145. Distress · 2025-08-14 [Protagenic Therapeutics delays 10-Q after approving move to virtual model](https://aibio.space/news/protagenic-therapeutics-delays-10-q-after-approving-move-virtual-model/) Protagenic Therapeutics said on August 14, 2025 that it cannot file its June quarter report on time, because its board approved a restructuring to a virtual operating model on August 8. The company expects to file by August 19, 2025, and the notice gives no cost or cash estimate for the restructuring. [PTIX](https://aibio.space/companies/protagenic-therapeutics/)
146. Distress · 2025-08-14 [TNF Pharmaceuticals (now Q/C Technologies) delays June quarter report](https://aibio.space/news/tnf-pharmaceuticals-now-q-c-technologies-delays-june-quarter-report/) TNF Pharmaceuticals says it needs more time to finish the financial statements for the six months ended June 30, 2025, and expects to file within the extension window. The notice does not say what is holding up the numbers. [QCLS](https://aibio.space/companies/q-c-technologies/)
147. Distress · 2025-08-14 [Denali Capital Acquisition Corp. (now Semnur Pharmaceuticals) delays June 10-Q](https://aibio.space/news/denali-capital-acquisition-corp-now-semnur-pharmaceuticals-delays-june/) Denali Capital filed a Form 12b-25 notice on August 14, 2025 saying it cannot file its June 30, 2025 quarterly report on time, because it is still completing its financial statements. The notice says the report will come no later than the fifth calendar day after the due date. [SMNR](https://aibio.space/companies/semnur-pharmaceuticals/)
148. Distress · 2025-08-14 [Windtree Therapeutics files late notice for quarterly report for June 30, 2025](https://aibio.space/news/windtree-therapeutics-files-late-notice-quarterly-report-june-30-2025/) The company said it needs more time to finalize its financial statements and related disclosures. It expects to file within five calendar days after the due date. [WINT](https://aibio.space/companies/windtree-therapeutics/)
149. Distress · 2025-08-12 [ORIC Pharmaceuticals cuts 20% of workforce, closes discovery research group](https://aibio.space/news/oric-pharmaceuticals-cuts-20-percent-workforce-closes-discovery/) ORIC expects a one-time cost of approximately $1.9 million for the workforce reduction. The company says cash and investments should fund its revised operating plan into 2H 2028, helped by $244 million in gross proceeds. [ORIC](https://aibio.space/companies/oric-pharmaceuticals/)
150. Distress · 2025-08-12 [Fate Therapeutics approves restructuring with 12% workforce reduction](https://aibio.space/news/fate-therapeutics-approves-restructuring-12-percent-workforce/) Fate Therapeutics (Nasdaq: FATE) expects $0.9 million to $1.2 million in severance charges in the third quarter of 2025. The company says it has $249 million in cash and investments and a runway through the end of 2027. [FATE](https://aibio.space/companies/fate-therapeutics/)
151. Distress · 2025-08-12 [Mosaic ImmunoEngineering delays its June 30, 2025 quarterly report](https://aibio.space/news/mosaic-immunoengineering-delays-june-30-2025-quarterly-report/) Mosaic ImmunoEngineering missed the 5:30 p.m. EDT August 14, 2025 deadline for its second-quarter report, citing financial reporting and close procedures. Its annual report warned it might have to cease operations if a deal with Oncotelic and note-holder waivers were not secured by June 30, 2025. [CPMV](https://aibio.space/companies/mosaic-immunoengineering/)
152. Distress · 2025-08-12 [ORIC cuts 20% of staff after $244 million gross financing, expects runway into 2028](https://aibio.space/news/oric-cuts-20-percent-staff-after-244-million-gross-financing-expects/) The company ended discovery research to focus on ORIC-944 and enozertinib. It does not expect to use its at-the-market facility for the foreseeable future. [ORIC](https://aibio.space/companies/oric-pharmaceuticals/)
153. Distress · 2025-07-29 [Merck approves 2025 restructuring program with about $3.0 billion in pretax costs](https://aibio.space/news/merck-approves-2025-restructuring-program-about-3-0-billion-pretax/) Merck expects to eliminate certain positions in sales, administrative and research and development organizations and expects annual savings of approximately $1.7 billion, substantially realized by the end of 2027. [MRK](https://aibio.space/companies/merck-mrk-xetr/)
154. Distress · 2025-07-29 [PharmaCyte Biotech delays annual report for year ended April 30, 2025](https://aibio.space/news/pharmacyte-biotech-delays-annual-report-year-ended-april-30-2025/) The company said it needs more time to prepare and review its financial statements. It plans to file within 15 days of the July 29, 2025 due date. [PMCB](https://aibio.space/companies/pharmacyte-biotech/)
155. Distress · 2025-07-23 [Rocket Pharmaceuticals starts restructuring with workforce reduction of about 30%](https://aibio.space/news/rocket-pharmaceuticals-starts-restructuring-workforce-reduction-about/) Rocket says the plan, approved by its board on June 18, 2025, aims to extend its operational runway into the second quarter of 2027. The company expects about $3.5 million in charges in the second half of 2025, against a 2024 operating cash outflow of $209.7 million. [RCKT](https://aibio.space/companies/rocket-pharmaceuticals/)
156. Distress · 2025-07-23 [Adicet Bio announces workforce reduction of about 30% and ends ADI-270 program](https://aibio.space/news/adicet-bio-announces-workforce-reduction-about-30-percent-ends-adi-270/) Adicet's board approved a cut of about 30% of its workforce on July 22, 2025 and ended its ADI-270 cancer program. The company expects about $2.3 million in charges and a cash runway into the fourth quarter of 2026, after a $117.1 million net loss in 2024. [ACET](https://aibio.space/companies/adicet-bio/)
157. Distress · 2025-07-11 [Artelo Biosciences' updated 2024 statements carry auditor going-concern doubt](https://aibio.space/news/artelo-biosciences-updated-2024-statements-carry-auditor-going-concern/) MaloneBailey said recurring losses and a net capital deficiency raise substantial doubt. Stockholders' equity fell to $2,857 thousand from $11,752 thousand. [ARTL](https://aibio.space/companies/artelo-biosciences/)
158. Distress · 2025-07-10 [Pacira BioSciences announces workforce reduction of 71 employees, about 8% of staff](https://aibio.space/news/pacira-biosciences-announces-workforce-reduction-71-employees-about-8/) Pacira is shutting down its 45-liter EXPAREL suite in San Diego and cutting 71 employees, about 8% of its workforce. It expects $2.4 million to $2.8 million of cash charges in the third quarter and about $13 million a year in lower operating expenses. [PCRX](https://aibio.space/companies/pacira-biosciences/)
159. Distress · 2025-07-10 [Pacira BioSciences cuts about 70 jobs as it decommissions 45-liter EXPAREL facility](https://aibio.space/news/pacira-biosciences-cuts-about-70-jobs-decommissions-45-liter-exparel/) Pacira is closing its 45-liter EXPAREL manufacturing system and cutting about 70 Technical Operations jobs, and the employee note it filed says the larger 200-liter process in San Diego and Swindon now supplies the product. [PCRX](https://aibio.space/companies/pacira-biosciences/)
160. Distress · 2025-07-09 [Jasper Therapeutics cuts workforce by about 50% and halts other programs to extend cash runway](https://aibio.space/news/jasper-therapeutics-cuts-workforce-about-50-percent-halts-other/) Jasper's board approved a corporate reorganization on July 8, 2025. The company will focus on briquilimab in chronic urticaria, expects $1.8 million to $2.2 million in severance cash costs, and its chief medical officer is leaving. [JSPR](https://aibio.space/companies/jasper-therapeutics/)
161. Distress · 2025-07-07 [Century Therapeutics plans about 51% workforce cut as CFO and chief development officer leave](https://aibio.space/news/century-therapeutics-plans-about-51-percent-workforce-cut-cfo-chief/) Century Therapeutics (Nasdaq: IPSC) expects to cut headcount by approximately 51% and record about $3.7 million in severance charges. Its CFO and Chief Development Officer will leave in July 2025. [IPSC](https://aibio.space/companies/century-therapeutics/)
162. Distress · 2025-07-07 [Pacira signs $300.0 million revolving credit facility and repays term loan](https://aibio.space/news/pacira-signs-300-0-million-revolving-credit-facility-repays-term-loan/) Pacira signed a $300.0 million senior secured revolving credit facility with Wells Fargo as administrative agent, and used part of it to repay its 2023 term loan A. The filing does not say how much was drawn. [PCRX](https://aibio.space/companies/pacira-biosciences/)
163. Distress · 2025-06-24 [Amarin licenses VAZKEPA in Europe to Recordati for $25 million upfront and starts restructuring](https://aibio.space/news/amarin-licenses-vazkepa-europe-recordati-25-million-upfront-plans/) Amarin will receive $25 million upfront and up to $150 million in milestones under a 59-country license. It also expects a global restructuring to cut operating costs by approximately $70 million annually. [AMRN](https://aibio.space/companies/amarin/)
164. Distress · 2025-06-24 [Amarin licenses Vazkepa in Europe to Recordati for $25 million upfront, plans restructuring](https://aibio.space/news/amarin-licenses-vazkepa-europe-recordati-25-million-upfront-plans/) Amarin is licensing Vazkepa in Europe to Recordati for a $25 million upfront payment and starting a restructuring that targets about $70 million in cost savings over the next 12 months, while the release gives no loss or cash-flow figures. [AMRN](https://aibio.space/companies/amarin/)
165. Distress · 2025-06-18 [Prothena cuts workforce by about 63% after ending birtamimab development](https://aibio.space/news/prothena-cuts-workforce-about-63-percent-after-ending-birtamimab/) Prothena expects $16 to $20 million in severance and related charges from the workforce reduction. Its Chief Regulatory Officer and Chief People Officer will leave effective August 1, 2025. [PRTA](https://aibio.space/companies/prothena/)
166. Distress · 2025-06-18 [Prothena cuts about 63% of workforce after ending birtamimab, expects $16 to $20 million in charges](https://aibio.space/news/prothena-cuts-about-63-percent-workforce-after-ending-birtamimab/) Prothena will cut about 63% of its workforce after ending birtamimab, and expects $16 to $20 million in charges, mostly cash. The 8-K gives no headcount, cash balance or savings figure. [PRTA](https://aibio.space/companies/prothena/)
167. Distress · 2025-06-12 [ADC Therapeutics plans about 30% workforce cut, U.K. closure, $100 million private placement](https://aibio.space/news/adc-therapeutics-plans-about-30-percent-workforce-cut-u-k-closure-100/) ADC Therapeutics approved a restructuring on June 11, 2025 that closes its U.K. research facility and cuts about 30% of its global workforce. The same day it agreed to a $100 million private placement priced at $3.53 per share. [ADCT](https://aibio.space/companies/adc-therapeutics/)
168. Distress · 2025-06-04 [Relay Therapeutics agrees to end Binney Street lease early and move to smaller space](https://aibio.space/news/relay-therapeutics-agrees-end-binney-street-lease-early-move-smaller/) Relay paid a lease modification payment of approximately $2.5 million and a relocation payment of approximately $3.5 million. It says the changes cut rent expense by approximately $16 million. [RLAY](https://aibio.space/companies/relay-therapeutics/)
169. Distress · 2025-06-02 [Actuate Therapeutics presentation repeats going-concern doubt and need for capital](https://aibio.space/news/actuate-therapeutics-presentation-repeats-going-concern-doubt-need/) Actuate Therapeutics filed a corporate overview dated May 31, 2025 that repeats its going-concern warning and says it needs capital to fund operations beyond the second quarter of fiscal 2025. The deck's survival figures are draft, unaudited data, and its progression-free survival result is not statistically significant. [ACTU](https://aibio.space/companies/actuate-therapeutics/)
170. Distress · 2025-05-30 [Adlai Nortye drops buparlisib after Phase III miss, plans workforce cut to preserve cash](https://aibio.space/news/adlai-nortye-drops-buparlisib-after-phase-iii-miss-plans-workforce-cut/) Adlai Nortye's Phase III BURAN trial of buparlisib missed its overall survival endpoint, the company is dropping the drug, and it plans to cut staff "to preserve cash," with the release giving no survival figures. [ANL](https://aibio.space/companies/adlai-nortye/)
171. Distress · 2025-05-29 [Keros Therapeutics plans workforce reduction of approximately 45% in restructuring](https://aibio.space/news/keros-therapeutics-plans-workforce-reduction-approximately-45-percent/) Keros's board approved a plan on May 28, 2025 to cut its overall workforce by about 45%, with about $3.2 million in severance charges and up to about $0.4 million in retention costs. The cuts follow the January 2025 early termination of the PAH trial over pericardial effusion events, though the company held $559.9 million in cash at the end of 2024. [KROS](https://aibio.space/companies/keros-therapeutics/)
172. Distress · 2025-05-29 [Keros Therapeutics drops cibotercept in PAH, cuts about 45% of staff](https://aibio.space/news/keros-therapeutics-drops-cibotercept-pah-cuts-about-45-percent-staff/) Headcount will fall to 85 full-time employees, with average annualized savings of about $17 million. The strategic alternatives review is still under way. [KROS](https://aibio.space/companies/keros-therapeutics/)
173. Distress · 2025-05-23 [Boundless Bio cuts about one-third of workforce, narrows pipeline, sees cash into 2028](https://aibio.space/news/boundless-bio-cuts-about-one-third-workforce-narrows-pipeline-sees/) Boundless Bio will drop current BBI-355 trial arms and test BBI-355 with BBI-825. The cut is expected to cost about $1.2 million. Cash and short-term investments were $138.3 million on March 31, 2025, with runway expected into the first half of 2028. [BOLD](https://aibio.space/companies/boundless-bio/)
174. Distress · 2025-05-15 [ReShape Lifesciences (now Vyome Holdings) files NT 10-Q, delaying its first-quarter 10-Q](https://aibio.space/news/reshape-lifesciences-now-vyome-holdings-files-nt-10-q-delaying-first/) The company says it needs more time to compile its financial statements for the quarter ended March 31, 2025, including to reflect the May 9, 2025 reverse stock split. [HIND](https://aibio.space/companies/vyome/)
175. Distress · 2025-05-15 [Exicure files NT 10-Q late-filing notice, needs more time on March 31, 2025 quarterly report](https://aibio.space/news/exicure-files-nt-10-q-late-filing-notice-needs-more-time-march-31-2025/) Exicure told the SEC on May 15, 2025 that it cannot file its quarterly report for the period ended March 31, 2025 on time, because it has not finished the accounting for its acquisition of GPCR Therapeutics USA, Inc. The company expects to file within the five-day extension that Rule 12b-25 allows, and it says the acquisition will make the quarter's results hard to compare with last year. [XCUR](https://aibio.space/companies/exicure/)
176. Distress · 2025-05-15 [Eloxx Pharmaceuticals files NT 10-Q, cites lack of funds for accountant review](https://aibio.space/news/eloxx-pharmaceuticals-files-nt-10-q-cites-lack-funds-accountant-review/) Eloxx says it cannot afford to engage its auditor to review first quarter 2025 financials, and it expects to disclose substantial doubt about its ability to continue as a going concern. It expects cash of $0.4 million at March 31, 2025. [ELOX](https://aibio.space/companies/eloxx-pharmaceuticals/)
177. Distress · 2025-05-15 [Plus Therapeutics (now Cerenome) says first-quarter 10-Q will be late over warrant accounting](https://aibio.space/news/plus-therapeutics-now-cerenome-says-first-quarter-10-q-will-late/) The company filed an NT 10-Q on May 15, 2025. It needs more time to account for warrants from a March 2025 private placement and expects lower stockholders' equity at March 31, 2025. [CNSY](https://aibio.space/companies/cerenome/)
178. Distress · 2025-05-15 [Aspira Women's Health delays first-quarter report to finish debt and equity accounting](https://aibio.space/news/aspira-womens-health-delays-first-quarter-report-finish-debt-equity/) Aspira says it needs more time to finish accounting for debt and equity deals from the first quarter, and it expects a smaller net loss helped by a milestone payment. [AWHL](https://aibio.space/companies/aspira-women-s-health/)
179. Distress · 2025-05-15 [Plus Therapeutics (now Cerenome) delays Q1 report over warrant accounting from March PIPE](https://aibio.space/news/plus-therapeutics-now-cerenome-delays-q1-report-warrant-accounting/) The company needs more time to finalize accounting for common stock purchase warrants issued in its March 2025 private placement. It expects a warrant liability that will lower stockholders' equity. [CNSY](https://aibio.space/companies/cerenome/)
180. Distress · 2025-05-15 [Greenwich LifeSciences delays first-quarter report, expects to file by May 20, 2025](https://aibio.space/news/greenwich-lifesciences-delays-first-quarter-report-expects-file-may-20/) The company filed a late-filing notice for its quarterly report for the three months ended March 31, 2025. Its lead candidate, GLSI-100, is in a Phase III trial that is still expanding. [GLSI](https://aibio.space/companies/greenwich-lifesciences/)
181. Distress · 2025-05-15 [Hepion Pharmaceuticals delays quarterly report for three months ended March 31, 2025](https://aibio.space/news/hepion-pharmaceuticals-delays-quarterly-report-three-months-ended/) Hepion says it is still compiling information for its March quarter 10-Q and expects to file within five calendar days. The notice previews research and development spending of $22,235, down from $2.5 million. [HEPA](https://aibio.space/companies/hepion-pharmaceuticals/)
182. Distress · 2025-05-15 [ReShape Lifesciences (now Vyome Holdings) delays first-quarter 10-Q](https://aibio.space/news/reshape-lifesciences-now-vyome-holdings-delays-first-quarter-10/) ReShape says a reverse stock split on May 9, 2025 is one reason its March quarter 10-Q needs more time. It expects to file within the five-day extension and says it does not expect a significant change in results. [HIND](https://aibio.space/companies/vyome/)
183. Distress · 2025-05-15 [Neuphoria Therapeutics delays quarterly report for period ended March 31, 2025](https://aibio.space/news/neuphoria-therapeutics-delays-quarterly-report-period-ended-march-31/) Neuphoria said it needs more time to compile supporting documents and let its auditor finish its review. It expects to file within the five-day extension period. [NEUP](https://aibio.space/companies/neuphoria-therapeutics/)
184. Distress · 2025-05-15 [NovelStem International delays first-quarter 2025 report as auditors finish review](https://aibio.space/news/novelstem-international-delays-first-quarter-2025-report-auditors/) NovelStem says its auditors need more time to finish their review of the March quarter, and it expects to file within five calendar days after the due date. NewStem, in which it holds about 31%, ceased operations and began liquidation in October 2024. [NSTM](https://aibio.space/companies/novelstem-international/)
185. Distress · 2025-05-15 [OSR Holdings (now OSR Health) delays quarterly report, expects $11.4 million loss](https://aibio.space/news/osr-holdings-now-osr-health-delays-quarterly-report-expects-11-4/) The company blamed a delay in finalizing its statements with its auditors after its February 14, 2025 business combination. [OSRH](https://aibio.space/companies/osr-health/)
186. Distress · 2025-05-15 [Exicure delays first quarter report over GPCR acquisition accounting](https://aibio.space/news/exicure-delays-first-quarter-report-gpcr-acquisition-accounting/) The company said it needs more time on the purchase price allocation for GPCR Therapeutics USA, Inc. It expects results to change significantly from the March 31, 2024 quarter. [XCUR](https://aibio.space/companies/exicure/)
187. Distress · 2025-05-14 [Citius Oncology 10-Q cites auditor's going-concern doubt](https://aibio.space/news/citius-oncology-10-q-cites-auditors-going-concern-doubt/) Citius Oncology reported $112 in cash at March 31, 2025 and negative working capital of about $31.7 million. Its parent had sufficient capital to fund it only through May 2025, and Nasdaq gave it until October 20, 2025 to fix its bid price. [CTOR](https://aibio.space/companies/citius-oncology/)[CTXR](https://aibio.space/companies/citius-pharmaceuticals/)
188. Distress · 2025-05-14 [Citius Pharmaceuticals 10-Q cites going-concern doubt and Nasdaq compliance](https://aibio.space/news/citius-pharmaceuticals-10-q-cites-going-concern-doubt-nasdaq/) The company had $26,410 in cash at March 31, 2025. Its own estimate says cash, including $1.735 million of net proceeds from an April offering, lasts only through May 2025, and it lost $21,792,751 in the six months to March 31. [CTXR](https://aibio.space/companies/citius-pharmaceuticals/)[CTOR](https://aibio.space/companies/citius-oncology/)
189. Distress · 2025-05-12 [Atara Biotherapeutics cuts workforce by about 30%, expects $1.4 million in severance](https://aibio.space/news/atara-biotherapeutics-cuts-workforce-about-30-percent-expects-1-4/) The company will keep about 23 employees after the cut and expects about $1.4 million in severance. Its latest annual report said cash of $42.5 million would not last twelve months and that about $15 million more was needed to pursue US approval of its lead drug. [ATRA](https://aibio.space/companies/atara-biotherapeutics/)
190. Distress · 2025-05-08 [Vor Biopharma winds down clinical operations, cuts 147 jobs and explores strategic alternatives](https://aibio.space/news/vor-biopharma-winds-down-clinical-operations-cuts-147-jobs-explores/) Vor estimates about $19.3 million in wind-down costs and plans to keep about 8 employees. Its chief financial officer and chief scientific officer were terminated without cause. [VOR](https://aibio.space/companies/vor-biopharma/)
191. Distress · 2025-05-08 [Liquidia files 2024 financials with going-concern doubt, revised debt accounting](https://aibio.space/news/liquidia-files-2024-financials-going-concern-doubt-revised-debt/) The auditor's report cites recurring losses. Management also changed how it accounts for two amendments to a $100.0 million royalty-backed financing. [LQDA](https://aibio.space/companies/liquidia/)
192. Distress · 2025-05-07 [Korro Bio announces 20% workforce reduction, expects cash runway into 2027](https://aibio.space/news/korro-bio-announces-20-percent-workforce-reduction-expects-cash-runway/) Korro Bio began a restructuring on May 7, 2025, cutting about 20% of its workforce and taking one-time charges of about $1.2 million. The company cut costs before its first interim data readout, and its net loss widened in the first quarter. [KRRO](https://aibio.space/companies/korro-bio/)
193. Distress · 2025-05-01 [Arvinas cuts workforce by about 33% and drops two Phase 3 vepdegestrant trials with Pfizer](https://aibio.space/news/arvinas-cuts-workforce-about-33-percent-drops-two-phase-3/) Arvinas expects about $10 million in severance and termination costs, mostly in the second quarter of 2025. It and Pfizer removed two planned Phase 3 combination trials from the joint development plan. [ARVN](https://aibio.space/companies/arvinas/)
194. Distress · 2025-05-01 [Pliant Therapeutics to cut workforce by about 45%, expects $3.6 million in severance costs](https://aibio.space/news/pliant-therapeutics-cut-workforce-about-45-percent-expects-3-6-million/) Pliant expects to substantially complete the reduction by the end of the second quarter of 2025, with about $3.6 million in severance and related benefits. The cut follows the discontinuation of its BEACON-IPF Phase 2b trial of bexotegrast. [PLRX](https://aibio.space/companies/pliant-therapeutics/)
195. Distress · 2025-05-01 [AN2 Therapeutics reports EBO-301 miss, projects $78.5 million in cash lasts into 2028](https://aibio.space/news/an2-therapeutics-reports-ebo-301-miss-projects-78-5-million-cash-lasts/) AN2 Therapeutics says the Phase 3 portion of its EBO-301 study missed its primary endpoint, and it projects $78.5 million in cash lasting into 2028 while it shifts to Chagas, melioidosis and oncology programs that have no human efficacy data yet. [ANTX](https://aibio.space/companies/an2-therapeutics/)
196. Distress · 2025-05-01 [Nymox says 20-F is late, citing unfinished work and slow vendor replies to auditors](https://aibio.space/news/nymox-says-20-f-late-citing-unfinished-work-slow-vendor-replies/) The company says it is still compiling required information for its annual report for the year ended December 31, 2024. [NYMXF](https://aibio.space/companies/nymox-pharmaceutical/)
197. Distress · 2025-05-01 [XORTX Therapeutics files late-filing notice for 2024 annual report](https://aibio.space/news/xortx-therapeutics-files-late-filing-notice-2024-annual-report/) The company says it needs more time for financial reporting, closing procedures and other disclosure items. [XRTX](https://aibio.space/companies/xortx-therapeutics/)
198. Distress · 2025-04-30 [XTL Biopharmaceuticals 20-F lists going-concern and delisting risks](https://aibio.space/news/xtl-biopharmaceuticals-20-f-lists-going-concern-delisting-risks/) The annual report for 2024 also lists dilution risk and the availability of capital for working capital needs. [XTLB](https://aibio.space/companies/xtl-biopharmaceuticals/)
199. Distress · 2025-04-29 [Entrada Therapeutics plans workforce reduction of about 20% to focus on Duchenne programs](https://aibio.space/news/entrada-therapeutics-plans-workforce-reduction-about-20-percent-focus/) The board approved a strategic plan on April 29, 2025 that expects about $2 million in charges, mostly severance. The company says its cash runway still reaches into the second quarter of 2027. [TRDA](https://aibio.space/companies/entrada-therapeutics/)
200. Distress · 2025-04-29 [Pfizer expands cost realignment program, adds $1.2 billion in expected savings](https://aibio.space/news/pfizer-expands-cost-realignment-program-adds-1-2-billion-expected/) Pfizer expects approximately $1.6 billion in one-time costs to deliver the added savings by the end of 2027. It now targets approximately $5.7 billion of total net cost savings from the program. [PFE](https://aibio.space/companies/pfizer-pfe/)
201. Distress · 2025-04-29 [Scinai files late 20-F notice over accounting for $29 million loan conversion](https://aibio.space/news/scinai-files-late-20-f-notice-accounting-29-million-loan-conversion/) The company cites the conversion of its European Investment Bank debt to preferred equity and personnel losses after year-end, and expects to file by May 15, 2025. [SCNI](https://aibio.space/companies/scinai-immunotherapeutics/)
202. Distress · 2025-04-29 [Entrada Therapeutics to cut about 20% of workforce in strategic plan](https://aibio.space/news/entrada-therapeutics-cut-about-20-percent-workforce-strategic-plan/) Entrada Therapeutics will cut about 20% of its workforce, with charges of about $2 million mostly in the second quarter of 2025. The 8-K gives the cash runway as lasting into the second quarter of 2027 in one place and into the second half of 2027 in another. [TRDA](https://aibio.space/companies/entrada-therapeutics/)
203. Distress · 2025-04-29 [Zhengye Biotechnology files late-filing notice, auditor needs more time on 20-F](https://aibio.space/news/zhengye-biotechnology-files-late-filing-notice-auditor-needs-more-time/) The company says it is still compiling information for its annual report for the year ended December 31, 2024. [ZYBT](https://aibio.space/companies/zhengye-biotechnology/)
204. Distress · 2025-04-24 [Caribou Biosciences cuts 47 jobs, drops programs, sees cash runway into second half of 2027](https://aibio.space/news/caribou-biosciences-cuts-47-jobs-drops-programs-sees-cash-runway/) Caribou will reduce its workforce by 47 employees, discontinue its lupus trial, a CB-012 trial and preclinical research, and focus on CB-010 and CB-011. It reported a preliminary $212.5 million in cash and securities at March 31, 2025. [CRBU](https://aibio.space/companies/caribou-biosciences/)
205. Distress · 2025-04-18 [Tempest Therapeutics cuts 21 of 26 employees as it explores strategic alternatives](https://aibio.space/news/tempest-therapeutics-cuts-21-26-employees-explores-strategic/) Tempest Therapeutics will cut 21 of its 26 full-time employees as it explores strategic alternatives, with cuts effective April 30, 2025. It expects about $1.5 million in cash costs, mostly severance, and its 2024 10-K said cash of $30.3 million would last at least 12 months. [TPST](https://aibio.space/companies/tempest-therapeutics/)
206. Distress · 2025-04-17 [Atea Pharmaceuticals authorizes $25 million buyback, reaches agreement with Radoff-JEC Group](https://aibio.space/news/atea-pharmaceuticals-authorizes-25-million-buyback-reaches-agreement/) The Radoff-JEC Group withdrew its director slate under the agreement. Atea's review of strategic alternatives with Evercore is still going. [AVIR](https://aibio.space/companies/atea-pharmaceuticals/)[COYA](https://aibio.space/companies/coya-therapeutics/)
207. Distress · 2025-04-17 [Cuprina Holdings files late notice for 2024 annual report on Form 20-F](https://aibio.space/news/cuprina-holdings-files-late-notice-2024-annual-report-form-20/) The Singapore-based company says it needs more time to finalize the report and plans to file within the fifteen-day grace period. [CUPR](https://aibio.space/companies/cuprina-cayman/)
208. Distress · 2025-04-15 [Abpro Holdings restates prior statements over understated license liabilities](https://aibio.space/news/abpro-holdings-restates-prior-statements-understated-license/) The company found it had understated liabilities under one of its license agreements and expects a $3.3 million increase in each affected period. Statements for three earlier periods should no longer be relied upon. [ABPO](https://aibio.space/companies/abpro/)
209. Distress · 2025-04-04 [MeiraGTx signs new New York lab lease and ends sublease early](https://aibio.space/news/meiragtx-signs-new-new-york-lab-lease-ends-sublease-early/) MeiraGTx will pay base rent of $111.00 per square foot a year on a new 14,235 square foot lab at 450 East 29th Street, and it moved to end its current sublease at the same address earlier than scheduled. The 8-K does not say what the total commitment will cost. [MGTX](https://aibio.space/companies/meiragtx/)
210. Distress · 2025-04-01 [Onconetix files NT 10-K late filing notice, says cash fell to $0.6 million at year end](https://aibio.space/news/onconetix-files-nt-10-k-late-filing-notice-says-cash-fell-0-6-million/) Onconetix needs more time to finalize its 2024 financial statements and expects to file within the fifteen-day grace period. It flagged lower cash, goodwill and intangibles, and new subscription and warrant liabilities. [ONCO](https://aibio.space/companies/oncopeptides/)
211. Distress · 2025-04-01 [ReShape Lifesciences (now Vyome Holdings) files NT 10-K late notice for 2024 annual report](https://aibio.space/news/reshape-lifesciences-now-vyome-holdings-files-nt-10-k-late-notice-2024/) ReShape Lifesciences filed a Form NT 10-K on April 1, 2025, saying it needs more time to compile information for its 2024 annual report. The notice does not explain the delay, and the company's 2023 annual report set a cost reduction target of about 55.4% for 2024. [HIND](https://aibio.space/companies/vyome/)
212. Distress · 2025-04-01 [Lyell Immunopharma to close West Hills plant and cut about 73 jobs, reiterates 2025 cash guidance](https://aibio.space/news/lyell-immunopharma-close-west-hills-plant-cut-about-73-jobs-reiterates/) Lyell expects $3.0 million to $4.0 million in closure and severance costs and net cash use of $175 million - $185 million in 2025. Its Chief Business Officer is also resigning. [LYEL](https://aibio.space/companies/lyell-immunopharma/)
213. Distress · 2025-04-01 [Eloxx Pharmaceuticals files NT 10-K, cannot fund audit and expects going concern doubt](https://aibio.space/news/eloxx-pharmaceuticals-files-nt-10-k-cannot-fund-audit-expects-going/) The late filing covers the year ended December 31, 2024. Eloxx expects cash and cash equivalents of $0.1 million at year end and lists four periodic reports it has not filed. [ELOX](https://aibio.space/companies/eloxx-pharmaceuticals/)
214. Distress · 2025-04-01 [Abpro Holdings delays annual report for fiscal year ended December 31, 2024](https://aibio.space/news/abpro-holdings-delays-annual-report-fiscal-year-ended-december-31-2024/) The company says it needs more time to prepare its financial statements and expects to file within the fifteen-day extension period. [ABPO](https://aibio.space/companies/abpro/)
215. Distress · 2025-04-01 [Emmaus Life Sciences delays 2024 annual report, sees revenue down more than $12 million](https://aibio.space/news/emmaus-life-sciences-delays-2024-annual-report-sees-revenue-down-more/) The company needs more time for the first audit by an accounting firm it retained in September 2024. It estimates a loss from operations of about $1.9 million for 2024. [EMMA](https://aibio.space/companies/emmaus-life-sciences/)
216. Distress · 2025-04-01 [Genprex delays 2024 annual report to finish financial statements and audit](https://aibio.space/news/genprex-delays-2024-annual-report-finish-financial-statements-audit/) The company says it needs more time on its 2024 financial statements and audit procedures. Its lead drug, REQORSA, has a Phase 2a trial whose enrollment rules changed twice in 2024 and 2025. [GNPX](https://aibio.space/companies/genprex/)
217. Distress · 2025-04-01 [Entero Therapeutics (now GridAI Technologies) delays 10-K over accounting review](https://aibio.space/news/entero-therapeutics-now-gridai-technologies-delays-10-k-accounting/) Entero says it is reviewing the accounting treatment of a significant transaction and needs more time for its 2024 annual report. The business section describes an ImmunogenX rescission that the company expects to close by June 30, 2025. [GRDX](https://aibio.space/companies/gridai-technologies/)
218. Distress · 2025-04-01 [Onconetix delays 10-K as cash falls to $0.6 million at year end](https://aibio.space/news/onconetix-delays-10-k-cash-falls-0-6-million-year-end/) The company expects to file within the 15-day grace period. Its cash was about $4.6 million at the end of 2023. [ONCO](https://aibio.space/companies/oncopeptides/)
219. Distress · 2025-04-01 [Tevogen Bio Holdings (now Tevogen) delays 10-K, sees 2024 loss of about $13.7 million](https://aibio.space/news/tevogen-bio-holdings-now-tevogen-delays-10-k-sees-2024-loss-about-13-7/) Tevogen said a change in outside accounting providers in September 2024 left it needing more time. It will keep reporting material weaknesses in internal controls. [TVGN](https://aibio.space/companies/tevogen/)
220. Distress · 2025-04-01 [Vaccinex delays annual report for fiscal year ended December 31, 2024](https://aibio.space/news/vaccinex-delays-annual-report-fiscal-year-ended-december-31-2024/) The company cited delays in completing its financial statements. It expects to file within the extension period of up to fifteen calendar days under Rule 12b-25. [VCNX](https://aibio.space/companies/vaccinex/)
221. Distress · 2025-03-31 [ABVC BioPharma files NT 10-K late filing notice for 2024 annual report](https://aibio.space/news/abvc-biopharma-files-nt-10-k-late-filing-notice-2024-annual-report/) The company says it is still completing its audit for the year ended December 31, 2024 and expects to file the 10-K within 15 calendar days of the due date. It does not expect a significant change in results. [ABVC](https://aibio.space/companies/abvc-biopharma/)
222. Distress · 2025-03-31 [Greenwich LifeSciences files NT 10-K, expects late annual report by April 15, 2025](https://aibio.space/news/greenwich-lifesciences-files-nt-10-k-expects-late-annual-report-april/) The company says it cannot file its 2024 annual report on time and expects to use the 15-day extension. Research and development expenses rose to $12,952,029, and the Phase IIb data behind its lead trial carry unresolved record gaps. [GLSI](https://aibio.space/companies/greenwich-lifesciences/)
223. Distress · 2025-03-31 [Matinas BioPharma files NT 10-K, says it needs more time to complete 2024 annual report](https://aibio.space/news/matinas-biopharma-files-nt-10-k-says-needs-more-time-complete-2024/) Matinas said it needs more time to review its financial statements for the year ended December 31, 2024 and plans to file its Form 10-K within the fifteen calendar day extension. It does not anticipate a significant change in results of operations. [MTNB](https://aibio.space/companies/matinas-biopharma/)
224. Distress · 2025-03-31 [Sunshine Biopharma files NT 10-K late-filing notice for 2024 annual report](https://aibio.space/news/sunshine-biopharma-files-nt-10-k-late-filing-notice-2024-annual-report/) The company says it needs additional time to complete its financial statements for the period ended December 31, 2024. It checked the box for filing within the fifteenth calendar day after the due date. [SBFM](https://aibio.space/companies/sunshine-biopharma/)
225. Distress · 2025-03-31 [RenovoRx files NT 10-K, says annual report will be late](https://aibio.space/news/renovorx-files-nt-10-k-says-annual-report-will-late/) RenovoRx (Nasdaq: RNXT) filed a late-filing notice for its 2024 annual report, citing technical accounting work with its current and former auditors. It expects to file within the 15-day grace period. [RNXT](https://aibio.space/companies/renovorx/)
226. Distress · 2025-03-31 [Aspire Biopharma Holdings (now Aspire-Lakewood Holdings) files NT 10-K, delays 2024 annual report](https://aibio.space/news/aspire-biopharma-holdings-now-aspire-lakewood-holdings-files-nt-10/) Aspire Biopharma told the SEC on March 31, 2025 that it needs more time to finish its 2024 financial statements. The notice gives no reason beyond that, and its narrative refers to a 10-Q deadline that does not match the annual report it is about. [ASBP](https://aibio.space/companies/aspire-lakewood/)
227. Distress · 2025-03-31 [Rein Therapeutics, formerly Aileron, files NT 10-K and expects $37.0 million impairment](https://aibio.space/news/rein-therapeutics-formerly-aileron-files-nt-10-k-expects-37-0-million/) Rein Therapeutics, formerly Aileron, filed a late-filing notice for its 2024 annual report and expects an impairment loss of about $37.0 million tied to a delay in developing LTI-01. The charge is non-cash, but the company's 2023 annual report already carried a going-concern warning. [RNTX](https://aibio.space/companies/rein-therapeutics/)
228. Distress · 2025-03-31 [ABVC BioPharma delays annual report for fiscal year ended December 31, 2024](https://aibio.space/news/abvc-biopharma-delays-annual-report-fiscal-year-ended-december-31-2024/) ABVC said it is still completing its audit and other disclosures. It expects to file the Form 10-K within the 15-day extension period. [ABVC](https://aibio.space/companies/abvc-biopharma/)
229. Distress · 2025-03-31 [Akari Therapeutics delays 2024 annual report over merger accounting](https://aibio.space/news/akari-therapeutics-delays-2024-annual-report-merger-accounting/) The company is still finishing the accounting for its November 14, 2024 business combination. It expects to file within the 15-day extension. [AKTX](https://aibio.space/companies/akari-therapeutics/)
230. Distress · 2025-03-31 [Aspire Biopharma (now Aspire-Lakewood Holdings) delays 2024 annual report](https://aibio.space/news/aspire-biopharma-now-aspire-lakewood-holdings-delays-2024-annual/) The company said it could not file by April 15, 2025, the original due date, because it needs more time for its financial statements. [ASBP](https://aibio.space/companies/aspire-lakewood/)
231. Distress · 2025-03-31 [Cyclacel (now Bio Green Med Solution) delays 2024 annual report](https://aibio.space/news/cyclacel-now-bio-green-med-solution-delays-2024-annual-report/) Cyclacel filed the notice on March 31, 2025, saying it needed more time to gather information. It expects to file within fifteen calendar days. [BGMS](https://aibio.space/companies/bio-green-med-solution/)
232. Distress · 2025-03-31 [Bioxytran delays annual report as auditor needs more time on 2024 audit](https://aibio.space/news/bioxytran-delays-annual-report-auditor-needs-more-time-2024-audit/) The company filed a late notice for its Form 10-K for the year ended December 31, 2024. It expects to file within the fifteen-day grace period. [BIXT](https://aibio.space/companies/bioxytran/)
233. Distress · 2025-03-31 [Celularity delays 2024 annual report, citing liquidity and staffing constraints](https://aibio.space/news/celularity-delays-2024-annual-report-citing-liquidity-staffing/) Celularity expects 2024 revenue of $54.2 million and a loss from operations of $37.3 million, figures it says are still under review. [CELU](https://aibio.space/companies/celularity/)
234. Distress · 2025-03-31 [DBV Technologies delays annual report while it works on private placement](https://aibio.space/news/dbv-technologies-delays-annual-report-while-works-private-placement/) DBV said talks on financing for its Viaskin Peanut program diverted management time. It plans to file the 10-K within the 15-day extension period. [DBV](https://aibio.space/companies/dbv-technologies/)
235. Distress · 2025-03-31 [Matinas BioPharma delays annual report for year ended December 31, 2024](https://aibio.space/news/matinas-biopharma-delays-annual-report-year-ended-december-31-2024/) The company needs more time to complete the review of its financial statements and plans to file within the fifteen calendar day extension. [MTNB](https://aibio.space/companies/matinas-biopharma/)
236. Distress · 2025-03-31 [Oncotelic Therapeutics delays 2024 annual report, expects to file within extension](https://aibio.space/news/oncotelic-therapeutics-delays-2024-annual-report-expects-file-within/) The company said it was unable to compile the financial information needed for a complete filing. It does not expect a significant change in results from the prior year. [OTLC](https://aibio.space/companies/oncotelic-therapeutics/)
237. Distress · 2025-03-31 [TransCode Therapeutics delays 2024 annual report to account for direct offering](https://aibio.space/news/transcode-therapeutics-delays-2024-annual-report-account-direct/) TransCode said it needs time to account for a registered direct offering that closed on March 25, 2025. It expects to file within the Rule 12b-25 extension period. [RNAZ](https://aibio.space/companies/transcode-therapeutics/)
238. Distress · 2025-03-31 [Rein Therapeutics delays 10-K, expects $37.0 million impairment on LTI-01](https://aibio.space/news/rein-therapeutics-delays-10-k-expects-37-0-million-impairment-lti-01/) The impairment follows a temporary delay of further clinical work on LTI-01. The company, formerly Aileron Therapeutics, needs more time to finish its impairment assessment. [RNTX](https://aibio.space/companies/rein-therapeutics/)
239. Distress · 2025-03-31 [RenovoRx files late notice for 2024 annual report, cites auditor accounting work](https://aibio.space/news/renovorx-files-late-notice-2024-annual-report-cites-auditor-accounting/) RenovoRx said it needs to complete technical accounting requirements with its current and former auditing firms. It expects to file within the fifteen-day grace period. [RNXT](https://aibio.space/companies/renovorx/)
240. Distress · 2025-03-31 [Reviva Pharmaceuticals delays 2024 annual report and expects to report material weaknesses](https://aibio.space/news/reviva-pharmaceuticals-delays-2024-annual-report-expects-report/) The company said it needs more time to finalize its financial statements and audit. It plans to file within the fifteen-day extension. [RVPH](https://aibio.space/companies/reviva-pharmaceuticals/)
241. Distress · 2025-03-31 [Sunshine Biopharma files late notice for annual report for December 31, 2024](https://aibio.space/news/sunshine-biopharma-files-late-notice-annual-report-december-31-2024/) The Fort Lauderdale company said it needs more time to complete its financial statements. It does not expect a significant change in results. [SBFM](https://aibio.space/companies/sunshine-biopharma/)
242. Distress · 2025-03-31 [Skinvisible delays annual report for year ended December 31, 2024](https://aibio.space/news/skinvisible-delays-annual-report-year-ended-december-31-2024/) The company said it could not compile all the information for its financial statements in time. It expects to file within the fifteen-day grace period. [SKVI](https://aibio.space/companies/skinvisible/)
243. Distress · 2025-03-31 [Spruce Biosciences delays annual report and flags going-concern doubt](https://aibio.space/news/spruce-biosciences-delays-annual-report-flags-going-concern-doubt/) Spruce expects cash to be insufficient to fund research and development for at least 12 months without new financing. It expects collaboration revenue to fall about 50%. [SPRB](https://aibio.space/companies/spruce-biosciences/)
244. Distress · 2025-03-31 [Savara ends $100.0 million at-the-market stock program with Evercore](https://aibio.space/news/savara-ends-100-0-million-market-stock-program-evercore/) Savara told Evercore it is ending a $100.0 million at-the-market sales agreement, effective April 2, 2025. The company says it owes no termination penalty and has sold no shares under the agreement since December 31, 2024. [SVRA](https://aibio.space/companies/savara/)
245. Distress · 2025-03-28 [TriSalus Life Sciences files NT 10-K, citing errors and material weaknesses](https://aibio.space/news/trisalus-life-sciences-files-nt-10-k-citing-errors-material-weaknesses/) TriSalus says it cannot file its 2024 annual report on time after finding errors in stock-based compensation and clinical trial expenses. It expects to file by the fifteenth calendar day after the due date. Preliminary 2024 revenue was $29.4 million. [TLSI](https://aibio.space/companies/trisalus-life-sciences/)
246. Distress · 2025-03-28 [Cell Source delays annual report for year ended December 31, 2024](https://aibio.space/news/cell-source-delays-annual-report-year-ended-december-31-2024/) The company says it is still compiling information for the report. It expects to file no later than the fifteenth calendar day after the due date. [CLCS](https://aibio.space/companies/cell-source/)
247. Distress · 2025-03-28 [Kairos Pharma delays annual report for 2024](https://aibio.space/news/kairos-pharma-delays-annual-report-2024/) The company expects to file within the 15-day extension period after its accounting staff finalizes the statements. [KAPA](https://aibio.space/companies/kairos-pharma/)
248. Distress · 2025-03-28 [TriSalus Life Sciences delays 10-K after finding errors and material weaknesses](https://aibio.space/news/trisalus-life-sciences-delays-10-k-after-finding-errors-material/) The company found errors in the timing of stock-based compensation and clinical trial expenses. It expects to file its annual report within fifteen calendar days of the due date. [TLSI](https://aibio.space/companies/trisalus-life-sciences/)
249. Distress · 2025-03-26 [Nkarta to cut 34% of workforce in restructuring, expects cash runway into 2029](https://aibio.space/news/nkarta-cut-34-percent-workforce-restructuring-expects-cash-runway-2029/) Nkarta is cutting 53 positions, about 34% of its staff, at an expected cost of $5.5 million to $6.5 million. It says its $380.5 million of cash and investments can fund operations into 2029, while the first clinical data from its lead program are not due until the second half of 2025. [NKTX](https://aibio.space/companies/nkarta/)
250. Distress · 2025-03-26 [Nkarta cuts 34% of workforce (53 positions), sees $380.5 million in cash lasting into 2029](https://aibio.space/news/nkarta-cuts-34-percent-workforce-53-positions-sees-380-5-million-cash/) Nkarta is cutting 34% of its workforce and freezing some hires, and it says $380.5 million in cash will fund operations into 2029. Its release reports no efficacy data for NKX019, and the trials enroll small groups. [NKTX](https://aibio.space/companies/nkarta/)
251. Distress · 2025-03-17 [Harrow files NT 10-K late filing notice for 2024 annual report, citing controls review](https://aibio.space/news/harrow-files-nt-10-k-late-filing-notice-2024-annual-report-citing/) Harrow says it needs more time for accounting analyses and its internal controls evaluation. It expects no changes to preliminary 2024 results, including revenues of between $198 million and $200 million. [HROW](https://aibio.space/companies/harrow/)
252. Distress · 2025-03-13 [Sutro Biopharma to cut about 50% of workforce in restructuring, names new CEO](https://aibio.space/news/sutro-biopharma-cut-about-50-percent-workforce-restructuring-names-new/) Sutro will deprioritize luvelta, exit its manufacturing facility and cut about 50% of staff, with costs of $40 million to $45 million. Jane Chung succeeds William J. Newell as CEO. Cash was $316.9 million at year-end. [STRO](https://aibio.space/companies/sutro-biopharma/)
253. Distress · 2025-03-11 [Helix Acquisition Corp. II (now BridgeBio Oncology Therapeutics) files annual report](https://aibio.space/news/helix-acquisition-corp-ii-now-bridgebio-oncology-therapeutics-files/) The blank-check company's annual report says it must liquidate if it does not close its deal with BridgeBio Oncology by February 14, 2026, and that doubt over its ability to continue is substantial. [BBOT](https://aibio.space/companies/bridgebio-oncology-therapeutics/)
254. Distress · 2025-03-10 [Alector to cut workforce by approximately 13%, expects $2.4 million in restructuring charges](https://aibio.space/news/alector-cut-workforce-approximately-13-percent-expects-2-4-million/) The company says the cut affects about 25 employees and will cost about $2.4 million. It still says cash lasts through 2026, while its lead frontotemporal dementia trial has yet to report and its term loan is secured on substantially all assets. [ALEC](https://aibio.space/companies/alector/)
255. Distress · 2025-03-05 [ALX Oncology approves 30% workforce reduction, will eliminate president and CSO role](https://aibio.space/news/alx-oncology-approves-30-percent-workforce-reduction-will-eliminate/) ALX Oncology's board approved a cut of about 30% of staff on Feb 28, 2025, and eliminates its president and chief scientific officer role. The company estimates about $2.2 million in severance and benefits for a lead drug that has not completed a pivotal trial. [ALXO](https://aibio.space/companies/alx-oncology/)
256. Distress · 2025-03-03 [ADMA Biologics files NT 10-K, says 2024 annual report will be late](https://aibio.space/news/adma-biologics-files-nt-10-k-says-2024-annual-report-will-late/) ADMA Biologics said on March 3, 2025 that KPMG LLP has not finished its audit of 2024 and expects to file the annual report by March 18, 2025. The notice attaches unaudited 2024 net income of 197,673 thousand dollars, against a 2023 net loss of 28,239 thousand dollars. [ADMA](https://aibio.space/companies/adma-biologics/)
257. Distress · 2025-03-03 [Ironwood Pharmaceuticals delays 10-K and expects a material weakness finding](https://aibio.space/news/ironwood-pharmaceuticals-delays-10-k-expects-material-weakness-finding/) Ironwood said it expects its internal control over financial reporting to be ineffective as of December 31, 2024. It plans to file within the 15-day grace period. [IRWD](https://aibio.space/companies/ironwood-pharmaceuticals/)
258. Distress · 2025-02-25 [Kiniksa ends abiprubart Phase 2b trial and terminates mavrilimumab license with MedImmune](https://aibio.space/news/kiniksa-ends-abiprubart-phase-2b-trial-terminates-mavrilimumab-license/) Kiniksa has incurred about $19 million in expenses from ending the Sjögren's trial and expects $14 million to $17 million more. It reported $243.6 million in cash, cash equivalents and short-term investments and no debt, and its 2024 net loss was $43.2 million. [KNSA](https://aibio.space/companies/kiniksa-pharmaceuticals-international/)
259. Distress · 2025-02-13 [Xencor says 2023 and 2024 interim financials can't be relied on, will restate royalty as debt](https://aibio.space/news/xencor-says-2023-2024-interim-financials-cant-relied-will-restate/) Xencor's audit committee concluded that a 2023 royalty deal with OMERS Life Sciences should be debt, not deferred income, and the company says its 2023 operating cash flow was overstated by $163.0 million. It also found tax misstatements. The company says cash and marketable debt securities are not affected. [XNCR](https://aibio.space/companies/xencor/)
260. Distress · 2025-02-13 [Bio-Rad restructuring to cut about 5% of workforce, with $45 million to $50 million in costs](https://aibio.space/news/bio-rad-restructuring-cut-about-5-percent-workforce-45-million-50/) Bio-Rad began the plan on February 7, 2025 and expects it to be substantially completed by the end of fiscal 2025. The company also made a binding offer to buy Stilla Technologies. [BIO](https://aibio.space/companies/nha-trang-vaccines-and-biological-products-jointstock/)
261. Distress · 2025-02-10 [Q32 Bio announces restructuring and workforce reduction to focus on bempikibart](https://aibio.space/news/q32-bio-announces-restructuring-workforce-reduction-focus-bempikibart/) Q32 Bio is ending its renal trial of ADX-097, cutting staff and betting on bempikibart in alopecia areata. It expects about $1.1 million in severance charges and says cash should last into the second half of 2026, but the release gives no cash balance. [QTTB](https://aibio.space/companies/q32-bio/)
262. Distress · 2025-02-06 [X4 Pharmaceuticals announces restructuring and workforce reduction of 43 employees, about 30%](https://aibio.space/news/x4-pharmaceuticals-announces-restructuring-workforce-reduction-43/) X4 will close its Vienna facility and pause preclinical programs to focus on mavorixafor in chronic neutropenia. It expects annual spending to fall by $30-35 million and believes its funds will last into the first half of 2026. [XFOR](https://aibio.space/companies/x4-pharmaceuticals/)
263. Distress · 2025-01-28 [Zentalis Pharmaceuticals announces restructuring with workforce reduction of approximately 40%](https://aibio.space/news/zentalis-pharmaceuticals-announces-restructuring-workforce-reduction/) The board approved the plan on January 22, 2025. Zentalis expects one-time costs of $7.0 million to $8.0 million and believes its cash will fund operations into late 2027. [ZNTL](https://aibio.space/companies/zentalis-pharmaceuticals/)
264. Distress · 2025-01-27 [Universe Pharmaceuticals says its 20-F will be late, expects $20.33 million net loss](https://aibio.space/news/universe-pharmaceuticals-says-20-f-will-late-expects-20-33-million-net/) The company expects a net loss of about $20.33 million for the year ended September 30, 2024, up from $6.16 million a year earlier. [UPC](https://aibio.space/companies/universe-pharmaceuticals/)
265. Distress · 2025-01-22 [Arvinas subsidiary ends New Haven lab lease, effective December 31, 2024](https://aibio.space/news/arvinas-subsidiary-ends-new-haven-lab-lease-effective-december-31-2024/) Under the January 15, 2025 agreement, Arvinas Operations owes no rent after the termination date if it clears the space by January 21, 2025. [ARVN](https://aibio.space/companies/arvinas/)
266. Distress · 2025-01-10 [Neogen files NT 10-Q late-filing notice, expects $461.4 million goodwill impairment](https://aibio.space/news/neogen-files-nt-10-q-late-filing-notice-expects-461-4-million-goodwill/) Neogen filed a late-filing notice on January 10, 2025 for its quarterly report for the quarter ended November 30, 2024. The company expects a $461.4 million goodwill impairment on its Food Safety unit and a net loss of $456.3 million, against a loss of $3.5 million a year earlier. [NEOG](https://aibio.space/companies/neogen/)
267. Distress · 2025-01-10 [Intellia plans about 27% net workforce cut, drops NTLA-3001, ends 2024 with $862 million](https://aibio.space/news/intellia-plans-about-27-percent-net-workforce-cut-drops-ntla-3001-ends/) Intellia says it is cutting its workforce by about 27% net in 2025 and dropping NTLA-3001 to focus on NTLA-2002 and nex-z. It ended 2024 with approximately $862 million and expects about $8 million in charges, but the release gives no headcount or savings figure. [NTLA](https://aibio.space/companies/intellia-therapeutics/)
268. Distress · 2025-01-07 [Cassava Sciences (now Filana Therapeutics) cuts 33% of workforce, reports $128.6 million cash](https://aibio.space/news/cassava-sciences-now-filana-therapeutics-cuts-33-percent-workforce/) After its Phase 3 ReThink-ALZ study of simufilam missed its co-primary endpoints, Cassava is cutting 10 employees, or 33% of its staff, at a one-time cost of about $0.4 million. It reported unaudited cash of about $128.6 million at December 31, 2024. [FLNA](https://aibio.space/companies/filana-therapeutics/)
269. Distress · 2025-01-07 [Cassava Sciences (now Filana Therapeutics) cuts workforce by about 33%, reports $128.6 million cash](https://aibio.space/news/cassava-sciences-now-filana-therapeutics-cuts-workforce-about-33/) The Alzheimer's drug developer expects about $0.4 million in one-time costs. The release gives no efficacy numbers for the two Phase 3 studies, and it still plans to report topline results from the one it is discontinuing. [FLNA](https://aibio.space/companies/filana-therapeutics/)
270. Distress · 2025-01-06 [CytomX Therapeutics to cut about 40% of headcount, expects $5 million to $6 million in charges](https://aibio.space/news/cytomx-therapeutics-cut-about-40-percent-headcount-expects-5-million-6/) The restructuring focuses the company on CX-2051 and its research collaborations. CytomX expects the changes to extend its cash runway into the second quarter of 2026. [CTMX](https://aibio.space/companies/cytomx-therapeutics/)
271. Distress · 2025-01-06 [Citius Oncology hires Jefferies to explore strategic alternatives](https://aibio.space/news/citius-oncology-hires-jefferies-explore-strategic-alternatives/) Citius Oncology has set no timeline for its strategic review, and the release says there is no assurance it will produce a deal. Its parent owns 92% of the company and has funded it since the subsidiary was formed. [CTOR](https://aibio.space/companies/citius-oncology/)[CTXR](https://aibio.space/companies/citius-pharmaceuticals/)
272. Distress · 2025-01-03 [Veru sells FC2 female condom business to Clear Future for $18.0 million in cash](https://aibio.space/news/veru-sells-fc2-female-condom-business-clear-future-18-0-million-cash/) The sale closed December 30, 2024. Veru expects about $12.5 million in net proceeds after a $4.2 million change of control payment to SWK Funding LLC, which ended a residual royalty agreement. [VERU](https://aibio.space/companies/veru/)
273. Distress · 2025-01-03 [Veru closes $18.0 million sale of FC2 female condom business](https://aibio.space/news/veru-closes-18-0-million-sale-fc2-female-condom-business/) Veru closed the sale of its FC2 female condom business on December 30, 2024 for $18.0 million in cash. After a $4.2 million change of control payment to SWK Funding and other fees, it estimates about $12.5 million in proceeds. [VERU](https://aibio.space/companies/veru/)
274. Distress · 2024-12-12 [Editas Medicine ends reni-cel program, cuts about 180 positions (65% of workforce)](https://aibio.space/news/editas-medicine-ends-reni-cel-program-cuts-about-180-positions-65/) The company expects costs of $55.0 million to $70.0 million for the discontinuation and $14.0 million to $18.0 million for the workforce reduction. It now sees cash lasting into the second quarter of 2027. [EDIT](https://aibio.space/companies/editas-medicine/)
275. Distress · 2024-11-21 [Iovance moves San Carlos headquarters to smaller space, cutting monthly rent](https://aibio.space/news/iovance-moves-san-carlos-headquarters-smaller-space-cutting-monthly/) A 24-month sublease with Vaxcyte at $99,549.53 per month replaces a lease with original monthly rent of $279,540.80. [IOVA](https://aibio.space/companies/iovance-biotherapeutics/)
276. Distress · 2024-11-15 [Aditxt delays quarterly report for period ended September 30, 2024](https://aibio.space/news/aditxt-delays-quarterly-report-period-ended-september-30-2024/) The company filed a late-filing notice on November 15, 2024. It plans to file the report no later than 5 days after the original due date. [ADTX](https://aibio.space/companies/aditxt/)
277. Distress · 2024-11-14 [Neurogene delays quarterly report for period ended September 30, 2024](https://aibio.space/news/neurogene-delays-quarterly-report-period-ended-september-30-2024/) The company says recent developments diverted management time and internal resources from its financial review. It expects to file within five days. [NGNE](https://aibio.space/companies/neurogene/)
278. Distress · 2024-11-14 [Scilex Holding delays third-quarter 10-Q, notice cites an ongoing review](https://aibio.space/news/scilex-holding-delays-third-quarter-10-q-notice-cites-ongoing-review/) The company missed the November 14, 2024 due date for its report on the quarter ended September 30, 2024. The notice warns that an ongoing review may identify errors or control deficiencies in its accounting practices. [SCLX](https://aibio.space/companies/scilex/)
279. Distress · 2024-11-13 [Cellectar Biosciences delays quarterly report after restating past results](https://aibio.space/news/cellectar-biosciences-delays-quarterly-report-after-restating-past/) The company found that certain warrants and preferred stock issued before 2023 had not been accounted for properly. It estimated cash of $34.3 million at September 30, 2024. [CLRB](https://aibio.space/companies/cellectar-biosciences/)
280. Distress · 2024-11-13 [Oruka reports $410,875 thousand in cash at September 30, 2024](https://aibio.space/news/oruka-reports-410-875-thousand-cash-september-30-2024/) A separate exhibit carries an audited balance sheet dated February 6, 2024, the company's inception. The auditor's report on it raises going-concern doubt. [ORKA](https://aibio.space/companies/oruka-therapeutics/)

---
Source page: https://aibio.space/distress/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Biotech distress: going concern, bankruptcy and layoffs", 2026-10-31, https://aibio.space/distress/